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ABSTRACT 
 
Background: Wnt signaling is fundamental to a myriad of biological processes 
including embryogenesis, organogenesis and tumorigenesis. It drives the 
expression of important genes for the proliferation, differentiation, maturation and 
activity of osteoblast-lineage cells. Pathways associated with Wnt signaling are 
regulated by their physiological antagonists such as sclerostin (SOST) as well as 
Wnt-5a that play important roles in the pathophysiology of several inflammatory 
conditions. 
 
Objectives: To compare the levels of SOST, Wnt-5a and TNF-Į between chronic 
periodontitis and periodontally healthy sites as well as to determine the correlation 
between clinical periodontal parameters and protein levels. 
  
Material and methods: In a cross-sectional assessment, 25 chronic periodontitis 
cases and 25 periodontally healthy controls were measured for probing pocket 
depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque 
index (PI) and percentage of radiographic bone loss. Gingival crevicular fluid 
(GCF) was collected cross sectionally from one periodontitis (deepest pocket) and 
one healthy (shallowest pocket) site in each case, and from one randomly selected 
site in each control subject.  The protein levels of SOST, Wnt-5a and TNF-Į in 
GCF were measured by ELISA.  The Shapiro-Wilk test was utilized to assess the 
normality of the distribution and non-parametric comparisons were performed. 
 
Results: Protein levels of SOST and Wnt-5a were similar between healthy and 
chronic periodontitis sites as well as the SOST levels between periodontally 
affected and healthy sites in the chronic periodontitis group (p > 0.05). 
Periodontally involved sites exhibited statistically significantly higher total Wnt-5a 
levels than the healthy sites in the periodontitis cases (p = 0.017).  When the data 
 v 
were expressed as concentration, significant differences were found among the 
study groups (p-values range from < 0.001 to 0.003). Significant positive 
correlations were found between SOST and 1) full-mouth PPD (p = 0.044), CAL (p 
= 0.010), BOP (p = 0.035); 2) PPD of the sampled sites (p = 0.037); and 3) sites 
with PPD 4-6 mm (p = 0.018). A trend of a negative correlation was found between 
SOST and sites with a CAL 0-2 mm (p = 0.052). Among all included subjects, 
males showed a statistically significantly higher Wnt-5a levels than females (p = 
0.031). 
 
Conclusions: Within the limitations of this cross-sectional study, sites with chronic 
periodontitis exhibited significantly elevated levels of Wnt-5a when compared to 
periodontally healthy sites in chronic periodontitis patients. No statistically 
significant association was found with SOST and TNF-Į levels.  
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INTRODUCTION 
 
Periodontal disease is a chronic inflammatory disease with multifactorial etiology. The 
onset and progression of the disease are initiated by microorganisms and results from the 
interaction between periodontal pathogens and the host immune response. Periodontal 
disease is characterized by destruction of the tooth supporting bone that leads to tooth 
loss if left untreated (Offenbacher 1996). Periodontitis and tooth loss may have a 
significant negative impact on oral health-related quality of life and lack of teeth causes 
functional and psychological problems (Al-Harthi et al. 2013; Nordenram et al. 2013). The 
high prevalence of periodontal diseases affects nearly half of the adults in the United 
States with 8.5% of these individuals having been diagnosed with severe periodontal 
disease (Eke et al. 2012). The economic burden associated with the management of 
periodontitis underscore the importance of implementing new diagnostic and therapeutic 
interventions (Eke et al. 2012).  
 
Bone is a dynamic and active tissue that in healthy adults is characterized by a balance 
between resorption mediated by osteoclasts and formation mediated by osteoblasts. 
Osteoblasts, in addition to their role in bone formation, mediate bone resorption via the 
regulation of osteoclasts (Kobayashi et al. 2003). Osteoclasts are responsible for bone 
resorption and both osteoclasts and osteoblasts are required for growth and remodeling. 
The regulation of bone metabolism is a complex process of different signal transduction 
pathways and depends on several local and systemic factors including cytokines, 
chemokines, hormones and biochemical stimulation (Phan et al. 2004, Crockett et al. 
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2011, Hofbauer and Heufelder 2001, Khosla 2001). Understanding the coupling between 
bone formation and bone resorption is crucial for better understanding and treating 
periodontal disease.  
 
Wnt signaling is fundamental to a myriad of biological processes including embryogenesis, 
organogenesis and tumorigenesis. It drives the expression of important genes for the 
proliferation, differentiation, maturation and activity of osteoblast-lineage cells (Krishnan 
et al. 2006).  Proteins associated with the Wnt signaling pathways regulate osteoblast 
differentiation. Wnt signaling also modulates osteoclast differentiation and activity, 
promotes commitment and differentiation of mesenchymal stem cells as well as 
suppresses chondrogenesis and adipogenesis leading to stimulation of osteoblasts 
(Rodda and McMahon 2006). Pathways associated with Wnt signaling are regulated by 
their physiological antagonists such as sclerostin (SOST) as well as Wnt-5a that play 
important roles in the pathophysiology of several inflammatory conditions. 
 
Traditional clinical criteria are insufficient for determining sites of active disease or for 
measuring the degree of susceptibility to further disease progression. A diagnostic tool 
may provide information to aid differential diagnosis, screening, presence, location, 
severity or staging and prognosis of a disease. Diagnostics based on oral fluids such as 
saliva and gingival crevicular fluid (GCF) have attracted scientific interest in periodontal 
research as well as in a number of systemic diseases including among others 
cardiovascular diseases and cancer (Taba et al. 2005, Rathnayake et al. 2013). GCF is a 
site-specific sampling method and less biased by any other oral pathological conditions 
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(Uitto et al. 2003). The evaluation of GCF can be used to assess quantitatively the site-
specific inflammatory status of a tooth. Molecules in saliva and GCF correlate with tissue 
inflammation and bone destruction but due to methodological differences in the existing 
literature, it is difficult to draw clear conclusions in how to utilize these inflammatory 
molecules in diagnosis. Therefore, while clinical measures remain reliable indices of 
disease history, highly specific and sensitive biomarkers are needed for the risk of disease 
diagnosis and monitoring of periodontal disease activity (Buduneli and Kinane 2011) 
The initial step in promoting a biomolecule as a biomarker is a cross-sectional assessment 
in different periodontal health and disease conditions. Cross-sectional studies have been 
utilized extensively to determine associations, generate hypotheses and ultimately further 
studies.  
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REVIEW OF THE LITERATURE 
 
Etiology and classification of periodontal diseases 
 
Plaque-induced periodontal diseases are highly prevalent and can affect up to 90% of the 
population worldwide. The manifestations of the disease ranges from gingivitis to 
periodontitis. Gingivitis affects 50-90% of adults based on the various definitions and 
represents a mild and reversible form of periodontal disease (Albandar and Rams 2002). 
Gingivitis is a reversible inflammation of the gingival tissues without loss of connective 
tissue attachment and alveolar bone (Armitage 1999). It may also be presented in a 
reduced but stable periodontium. In a classic study of human experimental gingivitis by 
Löe  and colleagues it was shown that clinical gingivitis developed within 21 days in the 
absence of oral hygiene which established the etiologic role of plaque in gingival 
inflammation (Löe  et al. 1967). Gingivitis can be reversed if inflammation is resolved and 
good plaque control is established (van der Weijden and Hioe 2005). However, if biofilm 
is not controlled, then gingivitis persists and may progress to periodontal disease 
(Kornman 2008). In an experimentally induced gingivitis model in young and healthy 
volunteers, an acute systemic inflammation resulted with enhanced systemic levels of C-
reactive protein (CRP), interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1 and 
activated monocytes which consisted of markers and mediators for vascular 
atherosclerotic disease (Eberhard et al. 2013). Therefore, the presence of gingival 
inflammation has been associated with systemic effects.  
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According to the broadly accepted classification system published in 1999, destructive 
periodontal diseases are classified into chronic periodontitis, aggressive periodontitis, 
periodontitis as a manifestation of systemic disease, necrotizing periodontal disease, 
abscesses of the periodontium, periodontitis associated with endodontic lesions and 
developmental or acquired deformities and conditions (Armitage 1999). Chronic 
periodontitis is the most common form of destructive periodontal disease (Papapanou 
1996) and is characterized by gingival inflammation with apical migration of the epithelial 
attachment onto the root surface and loss of connective tissue attachment and alveolar 
bone (Armitage 1995). It may be either localized or generalized depending on the number 
of affected sites. Localized periodontitis describes a condition with 30% or less affected 
sites, while in its generalized form more than 30% of the sites are affected (Armitage 
1999). Chronic periodontitis is associated with the presence of local etiologic factors such 
as microbial biofilm and subgingival calculus, gingival inflammation, periodontal pockets 
and attachment loss that progresses slowly (Brown and Löe  1993, Löe  1986, Papapanou 
and Wennstrom 1989). Aggressive periodontitis is a type of periodontal disease in which 
there is rapid destruction of periodontal ligament and alveolar bone which occurs primarily 
in otherwise systemically healthy young individuals (Armitage 1999). 
 
Different case definitions have been used to describe chronic periodontal disease having 
a great impact on reporting prevalence, severity and extent of the disease. Clinical 
examination is commonly performed to determine the presence of the disease as well as 
its severity and extent (Holtfreter et al. 2015).   Severity of periodontitis is commonly 
categorized based on the amount of clinical attachment loss. Slight or early periodontitis 
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exists when attachment loss ranges between 1-2 mm, moderate periodontitis when 3-4 
mm of attachment loss is present and severe periodontitis in the presence of at least 5 
mm of attachment loss (Armitage 2004). Although clinical attachment loss (CAL) is 
considered an accurate measurement of periodontal disease severity, it may occur even 
in the absence of disease such as in the case of overhang restorations by plaque 
accumulation (Page and Eke et al. 2007). A collaboration between the American Academy 
of Periodontology (AAP) and the Division of Oral Health at the Centers for Disease Control 
and Prevention (CDC) proposed new definitions for severe and moderate periodontitis 
(Page and Eke 2007). Patients with two or more interproximal sites with CAL ≥ 4 mm 
associated with two or more different teeth or two or more interproximal sites with a 
probing depth of ≥5 mm, not on the same tooth, were considered having moderate 
periodontitis. Severe periodontitis describes patients with two or more interproximal sites 
with CAL ≥ 6 mm, not on the same tooth, and the presence of one or more interproximal 
sites with a probing depth ≥ 5 mm. In this case definition, interproximal sites were only 
considered because the disease usually initiates and is most severe at interproximal sites 
minimizing also the risk of skewing the results due to gingival recessions (Page and Eke 
2007).  
 
Criteria for diagnosing periodontal diseases have been confusing throughout the years. 
The diagnosis of periodontal disease is primarily based on assessment of the destruction 
of periodontal tissues by the disease and it is not an assessment of the presence of the 
destructive disease process or activity. Currently, clinical examination is used to assess 
the presence of disease, while biochemical markers, microbes and histopathology are not 
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used in everyday clinical practice. The importance of the various criteria used for defining 
periodontal disease was demonstrated in a study by Manau et al. that included 14 different 
periodontitis definitions to examine the relationship between periodontitis and pregnancy 
(Manau et al. 2008). Six of the 14 definitions showed a statistically significant association 
of periodontitis with adverse pregnancy events, whereas the other eight did not reach 
statistical significance. Therefore, it is critical to identify evidence based criteria and 
standardized methodologies that will lead to an accurate diagnosis of the periodontal 
diseases.  
 
Risk factors of periodontal disease 
 
Etiologic factors of the periodontal diseases can be divided into modifiable and non-
modifiable risk factors including age, gender, smoking, diabetes, obesity and metabolic 
syndrome, osteoporosis, dietary calcium and vitamin D deficiency, stress and genetic 
factors (Genco and Borgnakke 2013). The prevalence and severity of periodontal disease 
increase with age which may reflect an individual’s cumulative oral history (Genco 1996, 
Löe et al. 1986). Severe periodontal disease and bone loss are rarely seen in individuals 
under 40 years old and the mean annual rate of bone loss differs among different 
population groups (Hugoson et al. 1992). An annual rate of 0.28 mm has been reported 
for individuals at the age of 70, while 0.07 mm was found in 25-year-old individuals 
(Papapanou and Wennstrom 1989). Males have also been reported to exhibit greater 
periodontal destruction compared to females, which may be associated with lower levels 
of oral hygiene among the male population (Slade and Spencer 1995). Although there is 
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no clear biological explanation for this association, the difference could also be attributed 
to sex hormones on the immune system (Haytac et al. 2013). In addition, possible 
interference by other confounding factors have been reported (Haytac et al. 2013).  
 
Smoking is considered an environmental factor that has been related to a dysbiotic 
subgingival microbial community which increases the risk for periodontal disease onset 
(Kumar et al. 2011). A number of epidemiological studies have demonstrated a significant 
association between smoking/tobacco use and periodontal disease in a variety of different 
populations suggesting a higher prevalence of severe periodontal disease, increased 
bone, attachment and tooth loss and gingival recessions than non-smokers (Bergstrom 
1989, Bergstrom et al. 2000). Smoking affects all components of the inflammatory 
response, both the innate and immune host response (Barbour et al. 1997, Johnson and 
Hill 2004). Neutrophils in smokers have been shown to have decreased chemotaxis, 
phagocytosis and adherence (Barbour et al. 1997, Johnson and Hill 2004, Kinane and 
Chestnutt 2000). Smoking is a well-established risk factor for periodontal disease that has 
been associated with a two- to eight-fold increased risk for periodontal attachment loss 
and bone loss with heavy smokers exhibiting a much higher risk (odds ratio of 5.6) than 
light smokers (odds ratio of 2.8) (Bergstrom 2003, Grossi et al. 1995, Torrungruang et al. 
2005, Tomar and Asma 2000). There is evidence of a positive relationship between the 
severity of periodontal disease and the number of pack-years smoked (Grossi et al. 1995).  
 
The strong association of periodontitis with a number of systemic medical conditions has 
generally been attributed to several factors including systemic distribution of periodontal 
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pathogens and local inflammatory mediators. Diabetes is one of the most studied risk 
factors for periodontal disease (Hajishengallis 2015). A meta-analysis has shown that 
individuals diagnosed with type 2 diabetes demonstrated a statistically significant higher 
mean attachment loss of 1 mm and a greater mean periodontal probing depth of 0.46 mm 
compared with non-diabetics (Chavarry et al. 2009). Individuals with type 2 diabetes with 
poor glycemic control - HbA1c ≥ 7% (Bandyopadhyay et al. 2010) and HbA1c ≥ 9% (Taylor 
et al. 1998) - demonstrated an increased risk for alveolar bone loss and more severe 
progression of periodontal disease when compared to those without diabetes and those 
with controlled diabetes (Bandyopadhyay et al. 2010, Taylor et al. 1998). The higher risk 
of diabetics for periodontal disease is attributed to the elevated levels of systemic markers 
of inflammation and the increased inflammatory reaction to bacterial challenge that lead 
to enhanced periodontal destruction (Brownlee 2005, Dandona et al. 2004). 
 
From a genetic perspective, chronic periodontitis was shown to exhibit a 50% heritability 
in a study of twins in which monozygotic twins were more similar than dizygotic twins with 
respect to all examined clinical measures (Michalowicz et al. 2000). Currently, a number 
of gene polymorphisms have been associated with periodontal disease with moderate to 
strong evidence increasing the odds for individual genetic variants up to 50% (Nibali et al. 
2017). Associations between single nucleotide polymorphisms in genes with chronic and 
aggressive periodontal disease (IL-1ȕ, IL-1RN, IL-6, IL-10, CD14, vitamin D receptor, 
MMP-1 and TLR4) have been reported (Laine 2012). Genome-wide association studies 
allow a “hypothesis-free” and unbiased analysis of the genome for detecting associations 
between genetic variants and periodontal disease (Vaithilingam et al. 2014). According to 
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the American Academy of Periodontology, “identifying these people with a genetic test 
before they even show signs of the disease and getting them into early intervention 
treatment may help them keep their teeth for a lifetime”.  
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The role of microbiota in periodontal diseases 
 
It has been reported that the human oral cavity harbors over 700 different bacterial 
species, of which more than 400 reside within the periodontal pocket (Paster et al. 2006). 
Development of the dental biofilm is initiated by initial colonizing bacteria and 
coaggregations between the initial colonizers (Streptococcus species), fusobacteria and 
late colonizers based on specific cell-cell interactions (Kolenbrander et al. 2010). In 
periodontitis, the microbial composition generally changes from a gram-positive biofilm to 
a more complex gram-negative anaerobic biofilm.  
 
A number of studies by Socransky’s team used whole genomic DNA probes and 
checkerboard DNA-DNA hybridization and categorized the composition of plaque from 
which bacteria were grouped into complexes based on the associations between bacterial 
species and prevalence in health and disease. The most common species present in 
supragingival plaque were those of the orange, yellow and blue complexes. Bacteria of 
the red complex (P. gingivalis, Tannerella forsythia and Treponema denticola) are 
generally associated with periodontal disease and subgingival plaque (Socransky et al. 
1998). The concept of color-coded complexes was adopted worldwide due to its 
convenience and simplicity. These studies by Socransky and colleagues used culture-
based or directed DNA approaches to determine the microbiota in periodontitis and health 
and showed that microbial counts for 14 species were generally higher in disease than 
health (Socransky et al. 1998). Such techniques cannot determine the presence of 
uncultivable species offering limited information on the total microbial diversity.  
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Novel molecular techniques including 16S rRNA cloning and sequence as well as 16S 
pyrosequencing provided a much broader picture of differences between periodontal 
disease and health. A systematic review of the literature included studies that used culture 
methods, protein electrophoresis techniques and technologies based on nucleic acid 
detection and showed that seventeen newly identified pathogens were associated with 
moderate evidence in patients with periodontitis (Perez-Chaparro et al. 2014). However, 
additional evidence is needed to establish new “true” periodontal pathogens. Phylotypes 
from the phyla Bacteroidetes, Candidatus Saccharibacteria, Firmicutes, Proetobacteria, 
Spirochaetes and Synergistetes have been more recently associated with periodontal 
disease (Perez-Chaparro et al. 2014).  
  
Microbial communities differ between periodontal health and disease. Periodontal disease 
is associated with a significantly different bacterial community profile, higher levels of gram 
negative organisms, increased species richness and more uncultivated species than 
periodontal health (Griffen et al. 2012). Peptostreptococcus, Filifactor, Megashpaera, 
Desulfobulbus species were significantly associated with periodontal disease, while 
Streptococcus, Abiotrophia, Gemella, Capnosytophaga and Veillonella species were 
associated with periodontal health. Differences were more pronounced between healthy 
and diseased subjects than between deep and shallow pockets, but the microbiome in 
deep sites demonstrated more genera and species as well as a greater range of diversity 
values than healthy sites. Microbiome differences have also been reported between race 
and smoking, while periodontal therapy reduces the microbial richness and diversity in the 
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supragingival microbiota (Kumar et al. 2005, Ge et al. 2013, Abusleme et al. 2013, 
Yamanaka et al. 2012). Therefore, the application of novel molecular techniques that can 
detect uncultivated species showed that periodontopathogens can be found in periodontal 
health and that the periodontal microbiota is more heterogeneous and diverse than 
previously thought (Hajishengallis and Lamont 2012).  
 
It is currently evident that the color-coded complexes require refinement because not only 
more periodontal pathogens have been shown to play a tremendous role in periodontal 
disease, but the organisms can also exhibit polymicrobial synergy. Understanding that 
only the presence of periodontal pathogens cannot result in periodontal disease, led to 
the polymicrobial synergy and dysbiosis model (PSD model) (Hajishengallis and Lamont 
2012). In this model, a diverse microbiota with key pathogens colonizes the periodontal 
pocket, disrupts the immune surveillance and elevates the virulence of the microbial 
community leading to a dysbiotic community that disrupts the tissue homeostasis 
(Hajishengallis and Lamont 2012). The transition from health to disease reflects changes 
in the abundance of species in the periodontal pocket. Dysbiosis is defined as a shift or 
imbalance of the relative abundance of species within a microbiome that is associated 
with disease such as periodontitis. This shift in conjunction with a dysregulated immune 
response leads to biofilm growth and uncontrolled inflammation. The subgingival dysbiotic 
environment is rich in immune and inflammatory mediators and provides nutrients for the 
bacteria to grow. The dysregulation of the host immune system can be a result of 
immunoregulatory defects such as leukocyte adhesion deficiency or by subversion of the 
host immune response by oral bacteria of the biofilm (Hajishengallis 2014).  P. gingivalis 
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has primarily been investigated for its role to modulate the host immune response, but 
other species also have the potential to modulate the host immune response 
(Hajishengallis 2014). P. gingivalis has been shown to act as a keystone pathogen due to 
its ability to remodel a commensal microbial community into a dysbiotic. Keystone 
pathogen is considered any pathogen that demonstrates a large effect on its environment 
disproportionately of its abundance. On the other hand, pathobionts are commensal 
microorganisms that may flourish and promote inflammatory disease under conditions of 
disrupted homeostasis. Treponema denticola, T. forsythia and Aggregatibacter 
actinomycetemcomitans are strongly associated with destructive inflammatory responses 
and subvert the host response by enhancing the survival of bystander species 
(Hajishengallis 2014).  
 
The role of host immune response in periodontal diseases 
 
Periodontal disease is defined as a multifactorial inflammatory disease which results from 
the interaction between periodontal pathogens and the host immune response. Microbial 
products initiate an inflammatory response leading to local tissue destruction and 
ultimately tooth loss (Offenbacher 1996). The virulence factors of the subgingival microbes 
disrupt the immune surveillance and elevate the virulence of the microbial community 
leading to a dysbiotic community and disruptive tissue homeostasis including periodontal 
ligament, cementum and alveolar bone (Hajishengallis and Lamont 2012). Although host 
response is protective against microbial invasion, both hypo- and hyper-responsiveness 
of a number of pathways can result in enhanced tissue destruction (Preshaw et al. 
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2004). Variations in disease onset and progression have been reported in individuals who 
harbor a similar microbial composition in their dental plaque as well as in patients in whom 
the periodontal pathogens vary (Baker and Roopenian 2002). Presence of systemic 
conditions, obesity, smoking, stress and aging characterize a susceptible host that can 
shift the polymicrobial synergy towards dysbiosis and may influence the progression and 
severity of periodontal disease (Hajishengallis 2014).  
  
Periodontal bone loss involves “two-way” interactions between the immunoinflammatory 
and bone-related cells (Graves et al. 2011). Periodontitis is initiated by bacterial plaque in 
the gingival crevice and occurs in four stages including colonization, invasion, 
inflammation and irreversible bone loss. More specifically, bacterial accumulation of a 
biofilm in the gingival sulcus leads to bacterial penetration of the epithelium and connective 
tissue which stimulates the acquired and innate immune response and ultimately leads to 
connective tissue attachment and alveolar bone loss (Graves et al. 2011). The interaction 
between host and bacteria leads to release of a number of cytokines and chemokines 
which play a pivotal role in periodontal tissue destruction. One of the critical components 
of the host response to bacteria or their products is a family of receptors, the toll-like 
receptors (TLRs). TLRs detect and bind microbial components including 
lipopolysaccharide (LPS), peptidoglycan, bacterial DNA, double-stranded RNA, and 
lipoprotein, which are called pathogen-associated molecular patterns (PAMPs) 
(Mahanonda and Pichyangkul 2007). These receptors lead to the activation of several 
transcription factors such as nuclear factor-kappaB and activator protein 1 (AP-1) through 
the mitogen-activated protein kinase (MAK) cascade resulting in the subsequent 
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production of cytokines and chemokines, many of which directly or indirectly stimulate 
osteoclast formation (Hayashi et al. 2010, Hans and Hans 2011, Mahanonda and 
Pichyangkul 2007). Chemokines contribute to periodontal bone loss because they can 
stimulate recruitment, differentiation and fusion of precursor cells to form osteoclasts or 
enhance osteoclast survival (Silva et al. 2007). 
 
Pro-inflammatory cytokines such as IL-1ȕ, IL-6 and TNF-Į link the innate and adaptive 
immune system by recruiting and activating adaptive immune related cells (Ebersole 2003, 
Kinane et al. 2011). Recognition of virulent pathogens leads to production of pro-
inflammatory chemokines and cytokines in macrophages, dendritic and epithelial cells; 
activation and recruitment of complement; emigration of circulating neutrophils; and 
ultimately stimulation of the adaptive immune responses (Di Benedetto et al. 2013, Kinane 
et al. 2007, Hajishengallis 2014, Kraus 2010). Neutrophils are present even in a healthy 
periodontium. Histological evidence has suggested that neutrophils form a barrier between 
the junctional epithelium and the dental biofilm (Page and Schroeder 1976). Their 
balanced function is important for the maintenance of periodontal health (Schenkein 
2006). Adverse neutrophil counts and genetic neutrophil defects have been associated 
with severe periodontal disease such as neutropenias, Chediak-Higashi syndrome, 
Papillon-Lefevre syndrome and granulomatous disease among others (Scott and Krauss 
2012). Neutrophils are considered the key protective cell type in periodontal tissues 
through their phagocytic action, by producing reactive oxygen species and secreting anti-
microbial molecules (Scott and Krauss 2012).  
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Adaptive immunity is also activated by pro-inflammatory cytokines recruiting circulating 
lymphocytes and monocytes followed by antigen presenting cells (Kinane et al. 2011). T-
cells and B-cells are activated through their interaction with the antigen presenting cells 
and then they proliferate and migrate to the site of inflammation. A shift from a 
predominantly T cell to B cell lesion in the progression from gingivitis to periodontitis has 
been reported and the mechanism of the pathogenesis of periodontal disease involves 
features of both the mucosal (IgA) and systemic (plasma cells and IgM) immune systems 
(Kinane and Lappin 2001). Periodontal lesions are primarily dominated by large numbers 
of B-cells and plasma cells (Seymour and Greenspan 1979).  
 
Initially, evidence supported that T-cells have a fundamental role in maintaining immune 
homeostasis and regulate autoimmunity (Gemmell et al. 2007). T-cell mediated adaptive 
immunity is highly dependent on innate immunity and the CD4+ T-cells were initially 
divided into two groups based on their pattern of cytokine production: T-helper 1 cytokines 
that are generally associated with inflammatory bone destruction and T-helper 2 cytokines 
that have been associated with less bone loss (Murphy and Reiner 2002, Colic et al. 2009). 
The T-helper 1/T-helper 2 paradigm in periodontal disease has been refined since T-
helper 17 and T regulatory cells were identified (Gaffen and Hajishengallis 2008). T-helper 
1/T-helper 2 is no longer valid due discrepancies in studies reported their involvement in 
diseased tissues, while T-helper 17 and regulatory T cells have been proposed to 
demonstrate a counterbalancing mechanism in the local environment with the presence 
of pro-inflammatory cytokines and TGF-ȕ to tip the balance in favor of T-helper 17 or a T 
regulatory response (Arun et al. 2011). 
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T-helper 17 cells play a pivotal role in barrier immunity, are involved in recruitment and 
activation of neutrophils, participate in immune surveillance and maintenance of barrier 
integrity as well as regulate antimicrobial peptide production. Increased proportions of 
Th17 cells and increased IL-17 levels are critical parameters in the pathogenesis of 
inflammatory diseases such as periodontal disease with a potential effect on osteoclastic 
mediators (RANKL, TNFĮ) (Cheng et al. 2014), while T regulatory cells exhibit protective 
roles against bone resorption through the expression of IL-10 and TGF-ȕ (Campbell et al. 
2016). Although various cells such as fibroblasts and osteoblasts can express RANKL, B- 
and T-cells are the major source of soluble RANKL revealing the importance of adaptive 
immunity in periodontal breakdown (Belibasakis and Bostanci 2012).  
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Tumor Necrosis Factor 
 
Tumor Necrosis Factor (TNF) is a pro-inflammatory cytokine that plays an important role 
in periodontal disease. Its expression in the GCF and periodontal tissues is increased 
during periodontal breakdown and acts synergistically with the RANK-RANKL system 
enhancing osteoclast differentiation leading to bone resorption, possibly in response to 
bacterial LPS (Stashenko et al. 1991, Salvi et al. 1998, Teles et al. 2009, Rogers et al.  
2007). TNF may increase osteoclast precursors and increase RANK expression on 
osteoclast precursors and M-CSF and RANKL expression in stromal cells including 
osteoblasts and synovial fibroblasts (Yao et al. 2006, Zhang et al. 2008, Teitelbaum and 
Ross 2006). In primates, an experimental model of periodontitis demonstrated that 
injection of TNF-Į antagonists reduced the number of inflammatory cells in the alveolar 
bone and the formation of osteoclasts revealing that TNF-Į is a significant component of 
the pathologic process of periodontitis (Assuma et al. 1998). Periodontal destruction was 
also accelerated following administration of recombinant TNF-Į in a rat periodontitis 
model, while in TNF receptor deficient mice, P. gingivalis-induced osteoclastogenesis was 
reduced when compared to wild-type controls demonstrating that TNF affects osteoclast 
formation as part of the host response to bacterial challenge (Gaspersic et al. 2003, 
Graves et al. 2001). This finding was also confirmed in a study by Garlet et al. which 
showed that TNF-Į receptor has a dual role in A. actinomycetemcomitans-induced 
experimental periodontitis (Garlet et al. 2007). TNF-Į receptor knockout mice developed 
significantly less inflammation and alveolar bone loss in association with significantly lower 
levels of IL-1ȕ, IFN-Ȗ and RANKL in gingival tissues compared to wild-type infected mice 
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even in the presence of higher levels of A. actinomycetemcomitans that were associated 
with lower levels of PMN-related antimicrobial mediator myeloperoxidase. Therefore, 
these findings provide evidence that TNF-Į upregulates the host response to bacteria and 
stimulates bone resorption in periodontitis (Garlet et al. 2007). 
 
TNF also inhibits bone formation by suppressing osteoblast differentiation. More 
specifically, TNF inhibits the expression of IGF-1, osterix (OSX), and runt-related 
transcription factor 2 (Runx2) (Osta et al. 2014, Algate et al. 2016). The inhibition of Runx2 
is mediated by the up-regulation of Smurf1 which is a negative regulator of osteoblast 
differentiation that causes the degradation of Runx2 (Lee et al. 2012). It has also been 
reported that TNF inhibits bone formation in rheumatoid arthritis by inducing the production 
of two Wnt signaling antagonists, DKK1 and SOST which control osteoclast and 
osteoblast differentiation (Goldring et al. 2013, Diarra et al. 2007, Schett 2007). TNF-Į 
may also inhibit the differentiation of mesenchymal stem cells into osteoblasts via the 
ubiquitin protein ligase Wwp1 in TNF transgenic mice expressing TNF-Į (Zhao et al. 
2011). However, there are multiple pathways that are generated by inflammatory 
mediators except for TNF-Į that activate osteoclasts and inhibit osteoblast formation. Anti-
TNF treatment has not shown a significant benefit in bone loss and fracture prevention in 
inflammatory diseases (Kawai et al. 2012). 
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Biology of the bone 
 
Bone is a living organ, highly dynamic and active mineralized connective tissue that 
consists of four types of cells: osteoblasts, bone lining cells, osteocytes and osteoclasts 
(Buckwalter et al. 1996). In bone, specific cells are responsible for the formation, 
resorption and maintenance of its architecture. Although in early childhood both bone 
modeling and remodeling occur, bone modeling is the predominant process, while bone 
remodeling predominates in adulthood (Kobayashi et al. 2003). Osteoblasts are 
mononucleate bone-forming cells that develop from pluripotent mesenchymal stem cells. 
They synthetize and secrete type I collagen, which is the major bone matrix protein, and 
osteoblasts also produce osteoid that mineralizes the newly formed bone. Proteins and 
signaling pathways such as bone morphogenetic protein (BMP), insulin-like growth factor 
(IGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming 
growth factor (TGF) ȕ and Wnt signaling pathways are important in regulating osteoblast 
differentiation and function (Cao and Chen 2005, Hughes et al. 2006, Day et al. 2005, 
Baron and Kneissel 2013). On the other hand, osteoclasts are the only type of cells that 
are able to resorb bone. They are large multinucleated cells and derive from mononuclear 
precursor cells of the monocyte/macrophage lineage (Teitelbaum and Ross 2003). 
Inflammatory diseases such as rheumatoid arthritis enhances the formation of osteoclasts 
through the synergistic effect of pro-inflammatory cytokines and RANKL as well as in 
conjunction with the differentiation of dendritic cells into osteoclasts (Chamoux et al. 
2009). 
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Bone is consistently being remodeled to maintain a healthy skeleton orchestrated by 
osteoblasts and osteoclasts. Bone remodeling is a cycle of three phases. Initially, bone 
resorption is mediated by osteoclasts, then the transition or reversal period follows and 
finally the bone formation phase which is mediated by osteoblasts (Sims and Gooi 2008). 
For other authors bone remodeling consists of four phases: activation of osteoclast 
progenitors via the RANKL/RANK/OPG pathway, bone resorption of the organic and 
mineral bone components, reversal and bone formation (Wittkowske et al. 2016). 
Mineralization and osteocytogenesis follows the bone formation. The bone remodeling 
cycle is shown in Figure 1. Bone remodeling is a physiological process, necessary for 
fracture healing and skeleton adaptation (Dallas et al. 2013). In normal bone remodeling, 
a balance between bone resorption and bone formation is ensured, while an imbalance 
may lead to pathological conditions and development of bone disorders. Excessive 
resorption by osteoclasts in conjunction with an imbalance bone formation contributes to 
bone loss (e.g. osteoporosis, periodontal disease etc), whereas the opposite may result 
in conditions such as osteopetrosis (Khosla et al. 2012, Sobacchi et al. 2013). The 
regulation of bone metabolism is a complex process of different signal transduction 
pathways and depends on several local and systemic factors including cytokines, 
chemokines, hormones and biochemical stimulation (Phan et al. 2004, Crockett et al. 
2011, Hofbauer and Heufelder 2001, Khosla 2001). Understanding the coupling between 
bone formation and bone resorption is crucial for better understanding and treating 
periodontal disease.  
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The primary regulatory mechanism of osteoclasts activity is mediated by members of the 
TNF receptor superfamily, RANK, RANKL and OPG. Periodontal diseases are a result of 
imbalances of this system (Teitelbaum and Ross 2000, Lerner 2006). RANKL is expressed 
at its highest levels in osteoblasts and stromal cells, while fibroblasts and activated T- and 
B-cells are also capable of expressing it (Yasuda et al. 1998, Takayanagi et al. 2000, Teng 
et al. 2000, Yun et al. 1998). During an inflammatory response, inflammatory mediators 
enhance the expression of RANKL. Stimulation of RANK by RANKL leads to differentiation 
of osteoclast progenitor cells and macrophages into fully differentiated osteoclasts 
resulting in bone resorption (Lerner 2004, Lerner 2006). Excessive bone resorption is 
associated with the presence of T-cells that is promoted by RANKL expression and 
cytokine production (Teng et al. 2000, Hofbauer and Heufelder 2001). On the other hand, 
OPG is considered as a decoy receptor which suppresses bone resorption and blocks 
osteoclastogenesis via binding to RANKL and inhibiting the interaction between RANKL 
and RANK (Simonet et al. 1997). OPG is expressed by human periodontal ligament cells, 
gingival fibroblasts, epithelial cells and human microvascular endothelial cells (Kanzaki et 
al. 2002, Sakata et al. 1999). Therefore, the interaction between RANK, RANKL and OPG 
is important in inflammation-induced bone resorption, such as periodontitis (Liu et al. 
2003). The RANKL/OPG ratio is the key pathway regulating the bone resorption and bone 
formation in a number of bone related disorders including periodontitis, rheumatoid 
arthritis, osteoporosis and bone cancer (Crotti et al. 2003, Belibasakis and Bostanci 2012). 
Imbalance in RANKL and OPG leads to alveolar bone destruction. Increased expression 
of RANKL has been reported in inflamed gingival tissues and in gingival crevicular fluid 
from periodontitis patients as well as in synovium from rheumatoid arthritis patients (Crotti 
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2003, Mogi et al. 2004, Gravallese et al. 2000), while OPG expression is decreased in 
gingival tissues and gingival crevicular fluid of periodontitis sites compared to healthy sites 
(Crotti et al. 2003, Mogi et al. 2004). With respect to the RANKL/OPG ratio, increased 
expression ratio is indicative of the presence of periodontal disease since RANKL and 
OPG gene expressions are differentially regulated in gingival tissues of different forms of 
periodontal disease (Bostanci et al. 2007).  
 
Wnt signaling pathways 
 
Bone metabolism is also regulated by the Wnt signaling pathway. Wnt signaling is 
fundamental to a myriad biological processes including embryogenesis, organogenesis 
and tumorigenesis (Kikuchi et al. 2009). Wnt proteins comprise a large family of secreted 
signaling glycoproteins that regulate cell proliferation, differentiation, apoptosis, survival, 
migration and polarity in a number of cell types (Kikuchi et al. 2009). It drives the 
expression of important genes for the proliferation, differentiation, maturation and activity 
of osteoblast-lineage cells (Krishnan et al. 2006). These Wnt proteins deliver their signs 
by binding to transmembrane receptor proteins. Proteins associated with the Wnt signaling 
pathways regulate osteoblast differentiation.  
 
The pivotal role of Wnt signaling in bone formation was displayed in humans with LRP5 
mutations (Gong et al. 2001). Loss of function by mutation of LRP5 leads to osteoporosis-
pdeudoglioma syndrome that is associated with decrease bone mass. In mice, inactivation 
of the LRP5 gene or overexpression of the human LRP5 function gene altered osteoblast 
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proliferation, differentiation and apoptosis (Kato et al. 2002, Babij et al. 2003). LRP5 is a 
Wnt receptor that upon activation leads to stabilization of cytoplasmic ȕ-catenin. 
Therefore, inactivation of the LRP5 gene affects the levels of ȕ-catenin in the cytoplasm. 
In addition, knockout of ȕ-catenin in mesenchymal osteoprogenitor cells blocks osteoblast 
differentiation, expression of mature osteoblast markers and mineralized bone formation, 
while it promotes chondrocyte differentiation (Day et al. 2005, Hill et al. 2005, Hu et al. 
2005, Cui et al. 2011). Disruption of endogenous inhibitors such as DKK1 or SOST 
increases the ability of Wnt proteins to stabilize ȕ-catenin and stimulate osteogenesis 
(Boyden et al. 2002, Li et al. 2005). Wnt signaling pathway impacts bone mass regulation: 
pathway activation results in an increase in bone mass, while the opposite is observed 
when the pathway is inhibited (Baron and Kneissel 2013). The effect of Wnt signaling 
pathway on bone mass regulation is shown in Figure 2.  
 
Wnt signaling also modulates osteoclast differentiation and activity. Wnt/ȕ-catenin 
signaling promotes commitment and differentiation of mesenchymal stem cells as well as 
suppresses chondrogenesis and adipogenesis leading to stimulation of osteoblasts 
(Rodda and McMahon 2006). More specifically, Wnt/ȕ-catenin signaling promotes the 
progression of Osterix1- expressing cells to osteoblasts and prevents the apoptosis of 
mature osteoblasts via activation of the Src/ERK and PI3K/Akt signaling cascades in both 
ȕ-catenin dependent and independent pathways (Almeida et al. 2005). In addition, the 
signaling pathway stimulates the production and up-regulation of OPG as well as the 
down-reguation of RANKL that reduces osteoclastogenesis and bone resorption (Glass 
26 
 
and Karsenty 2006, Spencer 2006).  The interaction between Wnt/ȕ-catenin signaling and 
bone cells is demonstrated in Figure 3. 
 
There are two pathways for Wnt signaling; ȕ-catenin-dependent canonical and ȕ-catenin-
independent non-canonical pathways (Gordon and Nusse 2006, Baron and Kneissel 
2013). An overview of the Wnt/ ȕ-catenin signaling is shown in Figure 4. In the absence 
of Wnt, glycogen kinase-3ȕ (GSK-3ȕ) and casein kinase 1 (CK1) phosphorylate ȕ-catenin 
at specific serine/threonine residues in the destruction complex which consists of the 
tumor supressors axin, the adenomatous polyposis (APC), GSK-3ȕ and CK1. The 
phosphorylated ȕ-catenin is ubiquitylated predominantly by the E3 ligase ȕ-TrCP leading 
to its degradation by the proteasomes. T cell factor/lymphoid enhancer factor (TCF/LEF) 
are repressed by Groucho in the nucleus. In the ȕ-catenin-dependent canonical pathway, 
Wnt activates multiple intracellular signaling pathways. Wnt proteins bind to a cell-surface 
receptor which consists of Frizzled and LRP5/6 and inhibit GSK-3ȕ which then promote 
the accumulation of ȕ-catenin. The accumulated ȕ-catenin is translocated to the nucleus, 
where it binds to the transcription factor TCF/LEF stimulating the transcription of Wnt 
target genes (Kikuchi et al. 2004, Gordon and Nusse 2006, Logan and Nussa 2004, Baron 
and Kneissel 2013). In the ȕ-catenin-independent non-canonical pathways, Wnt proteins 
bind to the receptor complex of Frizzled and ROR 2 or RYK which recruits dishevelles 
(DVL) and activate the planar cell polarity (PCP) pathway through the activation of RAC, 
RHO (small G protein) and Jun kinase (JNK)-dependent signals. The PCP pathway 
coordinates cell migration and polarity. Another ȕ-catenin-independent pathway, the Ca2+ 
pathway, is mediated by Wnt-5a binding to Frizzled and receptor-tyrosine-kinase-like 
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orphane receptor (ROR) that increase the intracellular Ca2+ concentration via protein 
kinase C (PKC) and calcium/calmodulin-dependent protein kinase (CaMK) II. This 
pathway inhibits the ȕ-catenin-dependent pathway and stimulates cell migration (Veeman 
et al. 2003, Qian et al. 2007, Kühl et al. 2000, Baron and Kneissel 2013).  
 
Mutations of the Wnt pathway have been associated with human skeletal diseases 
revealing its pivotal role in bone biology and skeletal development (Gong et al. 2011). 
Mutations of the Wnt canonical pathway are associated with bone mass homeostasis and 
skeletal patterning. As previously mentioned, LRP5 mutations are associated with 
osteoporosis pseudoglioma syndrome and with hereditary high bone mass (Gong et al. 
2011). Mutations in signaling components such as LRP4, WNT7A, WNT3 and SOST are 
also associated with congenital limb defects and digit fusion (Baron and Kneissel 2013). 
Mutations in genes-regulators of the Wnt pathway such as WNT9B, AXIN2, WTX and 
SOST have also been associated with bone diseases and congenital craniofacial 
anomalies including orofacial clefting, tooth agenesis, cranial skeletal dysplasia and 
cranial sclerosteosis (Chiquet et al. 2008, Lammi et al. 2004, Jenkins et al. 2008, 
Balemans et al. 2001).  
 
Regulation of the Wnt signaling pathways – Sclerostin (SOST) 
 
The Wnt pathway in bone is regulated by its physiological antagonists, SOST and 
Dickkopf-related protein 1 (DKK1) or Wnt ligands such as secreted Frizzed-related 
proteins and Wnt inhibitory factor 1/2. SOST is a secreted glycoprotein and important 
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regulator of Wnt signaling in bone and is primarily expressed by osteocytes (van Bezooijen 
et al. 2009). Osteocytes influence the balance between bone formation and resorption 
which is of paramount importance in maintaining normal skeletal health. SOST binds to 
LRP5/6 on the osteoblast surface and inhibits canonical Wnt signaling by blocking Wnt 
proteins from binding to the extracellular regions of LRP5 and 6 (Figure 5 and 6). 
Therefore, SOST decreases osteoblastogenesis and osteoblastic activity (Li et al. 2005, 
Rossini et al. 2013).  
 
On the other hand, SOST can also activate receptor activator of NF-kappaB ligand 
(RANKL) and promote osteoclast differentiation and bone resorption (Wijenayaka et al. 
2011). Increased SOST activity in bone results in low bone mass, while inhibition leads to 
increase bone mass and bone strength (Figure 6) (Li et al. 2005, Delgado-Calle et al. 
2016, Ominsky et al. 2017). SOST deficiency increases bone mass in mice and humans 
(Rossini et al. 2013). SOST-neutralizing monoclonal antibodies have been utilized in 
animal models of osteoporosis, ovariectomized rats and aged male rats showing 
enhanced bone formation, increased bone mass and bone strength (Li et al. 2009, Li et 
al. 2010). Similar findings were also reported in a ligature-induced periodontitis model in 
rats in which systemic treatment with anti-sclerostin antibody was delivered twice weekly 
for up to 6 weeks (Taut et al. 2013). Sclerosteosis, a rare autosomal recessive disorder, 
and van Buchem disease are related to loss of SOST expression and are characterized 
by bone overgrown, partial anodontia, delayed tooth eruption and malocclusion (Brunkow 
et al. 2001, Balemans et al. 2002, Stephen et al. 2001).  
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SOST is up-regulated by TNF-Į suggesting a potential link between inflammation and 
osteocyte function via the NK-kappaB pathway (Baek et al. 2014). Induction of SOST by 
TNF-Į in mature osteoblasts is primarily mediated by DKK-1. Blockade of DKK-1 
neutralizes the induction of SOST expression by TNF highlighting the cross-talk between 
TNF, DKK-1 and SOST (Heiland et al. 2010).  Wnt signaling pathway was found to be a 
promising mediator of inflammation that produced bony ankyloses in patients with 
spondyloarthritis. In this study, a proteoglycan-induced spondylitis (PGISp) mouse model 
was utilized and 12 weeks after initiation of inflammation, DKK1 and SOST levels were 
statistically significantly reduced in the spine PGISp in comparison with control mice. The 
decreased levels of the Wnt antagonists (DKK1 and SOST) in conjunction with the 
elevated Wnt signaling in spondylitis plays a key role in bone formation (Haynes et al. 
2012). In a study that aimed to identify biomarkers for bone metabolism in patients with 
ankyloses spondylitis, serum levels of SOST were correlated with CRP levels. More 
specifically, high CRP levels were associated with lower levels of SOST demonstrating a 
potential connection between inflammation and reduced inhibition of Wnt signaling 
(Klingberg et al. 2014). Even in a study with the ankyloses spondylitis that included 
treatment with TNF blockers, persistently elevated CRP levels were also correlated with 
low SOST levels (Saad et al. 2012).  
 
A cross-sectional study aimed to evaluate the involvement of SOST and DKK1 in human 
chronic periodontitis (Napimoga et al. 2014). In periodontal tissues of systemically healthy 
patients with chronic periodontitis, SOST and DKK1 were up-regulated implying a potential 
involvement in chronic periodontal disease. The levels of SOST were increased in the 
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peripheral serum of the periodontal disease patients compared to systemically and 
periodontally healthy patients. In 2015, a case-control intervention study included 54 
individuals and assessed the changes in the levels of SOST, OPG and RANKL in the 
gingival crevicular fluid (GCF) of periodontitis patients after non-surgical periodontal 
therapy (Balli et al. 2015). Although the total amounts and concentrations of SOST, OPG 
and RANKL showed reduction in the periodontitis patients six weeks after the treatment, 
significant differences were still observed when compared to healthy individuals. This 
might be attributed to the presence of residual periodontal pockets and active disease. 
 
Regulation of the Wnt signaling pathways – Wnt-5a 
 
Wnt-5a is an activator of the non-canonical signaling pathway and can bind to multiple 
receptors including Frizzled 2, 4, 5 and receptor tyrosine kinase-like orphan receptor 2 
(ROR2) (Liu et al. 2008). Wnt-5a can also both activate and inhibit the canonical Wnt 
signaling depending on the receptor context (Figure 7) (Leris et al. 2005).  It is the 
preferred Wnt/PCP activator ligand that binds to Frizzled 2 inhibiting Wnt/ȕ-catenin 
signaling (Sato et al. 2010, Mikels and Nusse 2006). Similarly, the presence of ROR2 
leads to inhibition of the canonical Wnt signaling by promoting ȕ-catenin degradation 
through a GSK3-independent pathway which involves the down-regulation of ȕ-catenin-
induced gene expression (Topol et al. 2003). The opposite was shown when Wnt-5a binds 
to Frizzled 4, 5 or LRP5 (He et al. 1997, Mikels and Nusse 2006). Wnt-5a inhibits bone 
formation by enhancing RANKL-induced osteoclastogenesis (Maeda et al. 2007) and its 
up-regulated expression may also enhance the expression of inflammatory-related genes 
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and intracellular reactive oxygen species through a novel NF-kappaB-dependent 
regulation (Zhao et al. 2015), which explains the increased expression of Wnt-5a in 
inflammatory diseases such as atherosclerosis, rheumatoid arthritis, periodontal disease, 
chronic apical periodontitis, spondyloarthitis as well as in patients with polycystic ovary 
surgery (Sen et al. 2000, Bhatt and Malgor 2014, Xu et al. 2014, Bougault et al. 2015). In 
synoviocytes from patients diagnosed with rheumatoid arthritis, the expression of Wnt-5a 
and Frizzled 5 was significantly up-regulated, while their blockage inhibited synoviocyte 
activation (Sen et al. 2000, Sen et al. 2001).  
 
Wnt-5a expression depends on TLR signaling and activation of the NF-kappaB in human 
antigen presenting cells in response to microbial challenge such as P. gingivalis 
(Blumenthal et al. 2006, Nanbara et al. 2012). Wnt-5a up-regulates the production of pro-
inflammatory cytokines such as IL-1ȕ, IL-6, IL-12 and IL-15 that are dependent on 
activation of the NF-kappaB pathway and inflammatory mediators in monocytes, 
macrophages, dendritic cells and microglia. A number of studies have also shown that 
Wnt-5a induces anti-inflammatory cytokines such as IL-10 in macrophages and dendritic 
cells and inhibition of the classical TLR4-NF-kappaB signaling pathway (Pereira et al. 
2008, Bergenfelz et al. 2012, Oderup et al. 2013). The effects and mechanisms of Wnt-5a 
on the regulation of inflammation remains unclear.  
 
In periodontitis, the expression of Wnt-5a mRNA is shown to be up-regulated in the 
gingival tissues of chronic periodontitis patients when compared to healthy gingiva 
(Nanbara et al. 2012, Maekawa et al. 2017). In a mouse model, Wnt-5a was proposed to 
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be an important target for intervention in periodontitis when exogenously added Wnt-5a 
enhanced LPS-induced inflammation (Maekawa et al. 2017). On the other hand, the same 
study demonstrated that secreted Frizzed-related proteins (sFRP)-5 was down-regulated 
by LPS from P. gingivalis and local treatment in mice inhibited inflammation, reduced the 
numbers of osteoclasts in bone tissues and ultimately inhibited bone loss (Maekawa et al. 
2017). An association between WNT-5A gene and severe chronic periodontal disease 
was also reported in a genome-wide association study by Divaris et al. (2013).  
 
Diagnostics in Periodontology  
 
Diagnosis of periodontitis has traditionally involved the clinical measurement of probing 
depth, attachment loss, evaluation of clinical signs of inflammation including bleeding, 
erythema, edema, exudate as well as radiographic evaluation of the alveolar bone. More 
recently, molecular determinants have been utilized to establish a biologically-based 
diagnostic method. These molecular techniques have been used to measure disease 
activity in regards to severity of tissue destruction and/or inflammation (Loos 2005).   
 
Early detection and prediction of risk for periodontal disease have always been a goal in 
the field of Periodontology. The use of clinical measures to determine periodontal status 
does not allow for the accurate prediction of periodontal disease progression or risk of 
development for periodontal disease (Goodson 1986). Diagnostics based on oral fluids 
have attracted significant scientific interest in periodontal research as well as in the 
systemic diseases such as cardiovascular diseases and cancer (Taba et al. 2005, 
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Rathnayake et al. 2013). Oral fluids including saliva, oral rinses and GCF can be used in 
a non-invasive and simple manner for diagnostic purposes. Both saliva and oral rinses are 
washed out oral fluids, while GCF is a site-specific sampling method and less biased by 
other oral pathological conditions (Uitto et al. 2003).  
 
Gingival crevicular fluid (GCF) 
 
GCF arises from the gingival plexus of blood vessels in the gingival connective tissue 
subjacent to epithelium lining the dentoginigval space (Alfano 1974). In individuals with a 
healthy periodontal status, GCF is a transudate filtrated from periodontal tissues into the 
periodontal sulcus that is not mixed with saliva until it flows out of the gingival crevice. 
GCF is formed as a result of an osmotic gradient in the crevice. On the other hand, trauma 
or bacterial plaque accumulation stimulate GCF that becomes an inflammatory exudate 
due to injury and a pathological process (Alfano 1974, Alfano et al. 1976, Griffiths et al. 
2003). Hence, GCF is considered protective due to the presence of host protective derived 
substances existing in the GCF including antibodies, cytokines, enzymes and tissue 
degradation (Griffiths et al. 2003).  
 
The collection of GCF is somewhat more demanding than the collection of other oral fluids 
and the avoidance of contamination of the GCF with other oral fluids is important (Griffiths 
et al. 2003). Another characteristic of GCF is its low amounts in the gingival crevice. In 
gingivitis and periodontally healthy gingiva, the amount of GCF is low and the detection of 
biomarkers may be difficult. GCF contains inflammatory mediators, enzymes with 
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collagenolytic activity, microbial and host cell enzymes, plasma proteins and proteins 
associated with the composition of the periodontium (Bowers et al. 1989). Collagen 
breakdown products are also identified in GCF revealing the connective tissue catabolism 
for both soft and hard tissues (Champagne et al. 2003). Over 65 GCF components have 
been examined as possible markers of periodontal disease progression (Armitage 2004). 
These components have been divided into three groups: host derived enzymes and their 
inhibitors, tissue breakdown products, inflammatory mediators and host response 
modifiers (Lamster and Ahlo 2007). 
 
GCF volume is correlated with gingival blood flow and varies based on the severity of 
periodontal inflammation. The fow rates may increase from 3 ȝL/h in healthy shallow 
pockets to 44 ȝL/h in deep periodontal pockets (Goodson 2003). Increase in GCF volume 
is associated with an increase in the severity of inflammation. More specifically, GCF 
volume may be 10-fold higher in sites with moderate periodontal disease (0.4 ȝL, 4-5 mm 
pockets) and 30-fold higher in sites with severe periodontal disease (1.5 ȝL, 6-9 mm 
pockets) compared to healthy sites (0.05 ȝL) (Goodson 2003).  Although GCF tends to 
increase as the inflammation becomes more severe, the quantity of GCF was considered 
a poor indicator of the severity of gingival inflammation (Hancock et al. 1979). Many other 
factors may increase the production of GCF such as smoking, oral contraceptives and 
pregnancy, or orthodontic treatment (Ustun and Alptekin 2007, Klinger 1982, Drummond 
et al. 2012). These other factors may affect the biomarkers concentration assessment and 
the interpretation of this evaluation may be misleading to a clinician/investigator. 
Contamination of GCF may occur with blood, saliva and plaque (Griffiths et al. 2003) and 
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prevention of the contamination is critical. GCF samples contaminated with blood or saliva 
should be discarded. Saliva contamination is prevented by air drying the sample site 
gently. Careful removal of the supragingival plaque is also recommended, because plaque 
can affect the GCF volume (Griffiths et al. 2003). Other discrepancies may occur due to 
evaporation and the recovery time following the sample collection.  
 
Collection of GCF has traditionally been accomplished with absorbent filter strip paper. 
The filter paper strip inserted into the entrance of the crevice until minimum resistance is 
felt in order to avoid trauma of the soft tissues (Brill 1959). Collection time generally varies 
from 30-60 seconds, while shorter duration collection time may be used to avoid 
contamination with blood or to avoid excessive GCF volume. This technique can be used 
as a noninvasive, simple and minimal trauma method (Griffith et al. 2003). Electronic 
devices (Periotron) are then used chairside to identify accurately and time efficiently the 
GCF volume. It measures the electrical capacitance of the wet paper strip and the greater 
the moisture in the strip the greater the increase in the capacitance in proportion to the 
volume of the fluid (Tözüm et al. 2004). Although these electronic devices may measure 
volumes between 0.1-1.0 ȝL, the measurements at the lower end of this range may lack 
significant accuracy (Griffiths et al. 2003). Measurement of GCF volumes from absorbent 
paper strip can be extremely reproducible and reliable with the same Periotron device, 
especially for fluid volumes greater than 0.2 ȝL. Calibration of each individual Periotron 
device will enhance volume accuracy (Chapple et al. 1995).  
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GCF can be used to assess quantitatively the site-specific inflammatory status. A 
biological marker is defined as “an indicator that signals events in biological systems or 
samples, and it is generally taken to be any biochemical, genetic or immunological 
indicator that can be measured in a biological specimen (Hulka and Wilcosky 1988, 
Schulte 1989). Five groups have been proposed by Wilson et al. (2007) and Kinane et al. 
(2011) for biomarkers based on the information that can provide for periodontal diseases.  
• Susceptibility: a biomarker that prospectively identifies individuals or sites at 
increased risk for periodontal disease.  
• Diagnostic: a biomarker that identifies the presence of periodontal disease 
• Prognostic: a biomarker that identified patients or sites most likely to respond to 
specific interventions 
• Predictive: a biomarker that predicts future progression of disease 
• Therapeutic: a biomarker that provides a quantifiable measure of response to 
periodontal therapy.  
 
Study designs 
 
Clinical research, according to Ahrens in 1992, is defined as studies on the mechanisms 
of human disease; studies on the management of disease; in vitro studies on materials of 
human origin; animal models of human health and disease; the development of new 
technologies; the assessment of health care delivery; and field surveys (Ahrens 1992). A 
number of different study designs exists in clinical research that generally may be 
separated into observational and experimental studies. Types of clinical research differ 
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based on whether the investigators assign the exposures or whether they observed 
standard clinical practice. 
 
 In an observational study, the researcher does not assign an exposure, but the exposure 
is the agent under investigation to determine its relationship with the health outcome. 
Studies that the researcher assigns the exposure or treatment are considered 
experimental. The next step in observation studies is the presence or not of a comparison 
group. Studies without comparison groups are called descriptive, while comparison groups 
are included in analytical studies. In the case of analytical studies, the temporal direction 
of the trial needs to be identified. Assessment of exposures and outcomes at one time 
point describes a cross-sectional study. On the other hand, if the study initiates with an 
exposure and the outcome is measured in several time points, then the study design is 
cohort. Cohort studies can be either concurrent or non-concurrent. In the group of 
analytical studies, a case-control study begins with an outcome and retrospectively 
investigates for an exposure (Grimes and Schulz 2002).  
 
Experimental studies can be designed with and without a comparison group. An 
uncontrolled trial of an intervention is an experiment because the investigator will direct 
the administration of a treatment, but a concurrent control group is not included in the 
design phase of the study. Uncontrolled trials of an intervention are useful as part of the 
early phases of drugs and device development. Experimental studies with a comparison 
group may be divided into two groups based on the presence of randomization: non-
randomized and randomized. Non-randomized controlled trials of an intervention are used 
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primarily when it is unethical or unfeasible to use a random treatment allocation process. 
When an experiment follows a group of participants over time and has both a comparison 
group and uses a random process for treatment allocation, it is called a randomized clinical 
trial. Randomization ensures that the groups under investigation are similar at baseline so 
any future differences between the groups will likely attributed to the intervention. This 
allows the study to provide strong evidence of cause and effect. Randomized clinical trials 
are subdivided into large simple trials, pragmatic trials, explanatory trials and phase II/III 
trials.  
 
Cross-sectional studies provide descriptive data on prevalence of diseases which provide 
valuable information for planning analytical studies. In this study design, exposures, which 
are also called risk factors, and disease endpoints are assessed simultaneously. Cross-
sectional data cannot provide any assessment of incidence rates but provide estimates of 
disease prevalence, proportions and estimates of measures of association in order to 
correlate putative etiologic factors with outcome. Therefore, the question addressed by a 
cross-sectional study is whether there is an association between a particular factor and a 
disease or other events. Outcome associations identified from cross-sectional studies are 
used to generate hypothesis and ultimately provide evidence/data to initiate further studies 
such as longitudinal investigations.  
 
Cross-sectional studies have been utilized extensively as an initial step to determine 
associations. These studies are relatively inexpensive and can help determine where 
funding might be directed to provide maximum benefit. They usually are also quicker to 
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conduct than case-control or cohort studies since no follow-up is needed. One of the 
limitations of a cross-sectional study is that a causal relationship cannot be established. 
This is because confounding factors cannot be controlled by the investigator. Sometimes 
it is simply unknown which came first, the exposure or the disease. With cross-sectional 
studies, there is a risk to infer a causal relationship, exposure to disease, when none may 
exist. In addition, rare conditions cannot efficiently be studied with cross-sectional studies 
because a very large number of subjects may be required to yield a sufficient number of 
diseased individuals. Other study designs including case-series and case-control studies 
which include patients who already have the disease are more useful than cross-sectional 
assessment. When cross-sectional associations are used with large representative 
samples that permit a valid generalization, they can provide useful information about the 
prevalence of risk factors and disease states.  
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RATIONALE AND PURPOSE 
 
Molecular determinants have been utilized to establish a biologically-based diagnostic 
method and to measure disease activity in regards to severity of tissue destruction and/or 
inflammation. There is considerable interest in the identification, validation and clinical 
application of periodontal biomarkers, because traditional periodontal diagnostic 
parameters including probing depth, attachment level, bleeding on probing and 
radiographic assessment of alveolar bone level are inherently limited as these clinical 
parameters are a measure of disease history. The disease status cannot be assessed 
since clinical attachment loss readings by a periodontal probe and radiographic evaluation 
of alveolar bone loss measured damage requires a 2-3 mm change before a site can be 
identified as having progression. The primary goal for periodontal biomarkers is to allow 
earlier detection of disease activity or risk of disease progression and sooner therapeutic 
intervention.  
 
Inflammatory osteoclastogenesis mediated by pro-inflammatory mediators characterizes 
the central pathologic process of periodontitis. Therefore, identification of bone markers 
of periodontal disease may provide information about the presence of current disease 
activity and allow clinicians to recognize highly susceptible patients or site that are at risk 
for disease progression. Ultimately the goal is to improve the clinical management of 
periodontal patients and prevent tissue destruction. The initial step in promoting a 
biomolecule as a biomarker is a cross-sectional assessment of patients/sites with different 
periodontal conditions.  
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Wnt/ȕ-catenin signaling promotes differentiation of mesenchymal stem cells and 
suppresses chondrogenesis and adipogenesis leading to stimulation of osteoblasts. It also 
reduces osteoclastogenesis and bone resorption via the up-regulation of the osteprotegrin 
and down-regulation of RANKL. The Wnt/ȕ-catenin signaling is associated with 
inflammatory responses driven by innate and adaptive immunity via the NF-kappaB 
pathway. Wnt signaling pathways are regulated by their physiological antagonists such as 
sclerostin (SOST) as well as Wnt-5a that play important roles in the pathophysiology of 
several conditions such as osteoporosis and arthritis. 
 
The rationale for this study was to assess the involvement of the Wnt signaling pathway 
in chronic periodontitis and to examine whether SOST and Wnt-5a in the GCF can be 
used as diagnostic markers of periodontal disease status.  
 
This research addresses the following hypotheses:  
1) Sites with chronic periodontitis exhibit elevated protein total amounts and 
concentrations of SOST, Wnt-5a and TNF-Į compared to periodontally healthy sites.  
2) There is a positive correlation between clinical parameters including probing depth and 
clinical attachment loss with the protein total amounts and concentrations of SOST, Wnt-
5a and TNF-Į in GCF. 
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The specific aims of the study are: 
1) To compare the protein total amounts and concentrations of SOST, Wnt-5a and TNF-
Į in GCF between chronic periodontitis and periodontally healthy sites.  
2) To determine the correlation between clinical parameters including probing depth and 
clinical attachment loss with the protein total amounts and concentrations of SOST, Wnt-
5a and TNF-Į in GCF. 
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MATERIAL AND METHODS 
 
Study design 
 
This study was designed to cross-sectionally compare the concentration and total 
amounts of GCF constituents (SOST, Wnt-5a, TNF-Į) in periodontal health and disease. 
Two groups of individuals classified as having chronic periodontitis and periodontal health 
were selected for the study. Adult patients with chronic periodontitis ( 2 inter-proximal 
sites with a clinical attachment loss of  4 mm and  2 inter-proximal sites with probing 
pocket depth of  5 mm and radiographic assessment alveolar bone loss of  40%) were 
invited to participate in the study. A full-mouth series of x-rays within the past 12 months 
was required to assess the diagnosis of chronic periodontitis. Adults with probing pocket 
depths  4 mm, clinical attachment loss  2 mm and no evidence of radiographic bone 
loss were characterized as periodontally healthy patients, and they were included as 
healthy control subjects. A full-mouth series of intraoral radiographs within the last five 
years was needed to confirm the presence of a healthy periodontium. Demographic 
characteristics including age, gender, race, smoking status and medical history were also 
recorded. The purpose and the procedures of the study were completely reviewed for 
each evaluated subject, and all patients were given a written consent and HIPAA form in 
accordance with the Declaration of Helsinki. The study was approved by the Institutional 
Review Board at the University of Minnesota (Study number: 1511M80307). 
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Patient recruitment  
 
The periodontitis group consisted of patients who were seeking periodontal treatment at 
the University of Minnesota School of Dentistry, while healthy individuals were identified 
from patients visiting the Graduate Periodontology clinic for treatment unrelated to 
periodontal disease. Staff as well as dental and hygiene students were also recruited to 
participate in the study as healthy volunteers. All eligible individuals who participated in 
this investigation were compensated with $20.  
 
Inclusion and exclusion criteria 
 
During preliminary screening, all participants were examined for potential eligibility for 
participation in the study based on the following criteria:  
1) at least 18 years old,  
2) systemically healthy,  
3) 15 permanent teeth (excluding third molars) are present,  
4) absence of systemic medical conditions that could impact the periodontal status or any 
bone-related diseases (diabetes mellitus, HIV infection, bleeding disorders, 
immunosuppressive chemotherapy, osteoporosis, ankylosis spondylitis, recent bone 
fractures, rheumatoid arthritis, chronic endogenous hypercortisolism) that might influence 
SOST, Wnt-5a and any additional target molecule levels in GCF levels. 
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Moreover, individuals were excluded from the study if they exhibited any of the following 
criteria:  
1) need for antibiotic pre-medication,  
2) pregnancy or lactation,  
3) antibiotic usage in the last 6 months,  
4) periodontal treatment in the last year,  
5) regular user of NSAIDs,  
6) use of glucocorticoids, bisphosphonates or denosumab,  
7) periapical lesions,  
8) orthodontic appliances, 
9) adults lacking the capability to consent. 
 
Clinical examination 
 
All subjects underwent a periodontal examination including measurement of probing 
pocket depth-PPD (distance from the deepest point of the periodontal pocket to the 
gingival margin) and clinical attachment loss-CAL (distance from the deepest point of the 
periodontal pocket to the cementoenamel junction) as well as the presence of plaque and 
bleeding on probing at six sites around each tooth using a Michigan probe with Williams 
markings. Percentage of sites with PPD = 1-3 mm, PPD = 4-6 mm and PPD ≥ 7 mm as 
well as percentage of sites with CAL = 0-2 mm, CAL = 3-4 mm and CAL ≥ 5 mm were also 
recorded. All measurements were performed at the same six sites of each tooth: mesio-
buccal, buccal, disto-buccal, mesio-lingual, lingual, and disto-lingual. Both plaque and 
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bleeding on probing were recorded as binary variables, either presence or absence. 
Calibrated examiners performed the clinical periodontal measurements. Calibration trials 
were conducted to determine intra- and inter-examiner reliability for the measurement of 
PPD and CAL.  
 
 
Calibration 
 
Prior to conducting a research project in periodontology, a calibration trial should be 
completed to determine examiners’ reproducibility level and measurement variation 
(error). This is crucial especially when different examiners are used for the recruitment of 
potential patients. The calibration trial consists of repeated measurements on selected 
patients in order to determine the level of agreement. The importance of a calibration trial 
is based on the ability to obtain similar measurements among all examiners as well as 
each examiner separately. The dimension of the periodontal probe tip, the applied forces, 
the angle of insertion and the root contour influence the depth recorded (Listgarten 1980). 
For this study, all measurements were carried out using the same type of periodontal 
probe (Michigan probe with Williams markings) and training was provided to all examiners. 
Calibration trials were conducted to determine intra- and inter-examiner reliability for the 
measurement of PPD and CAL. 
 
Inter-examiner reproducibility or agreement or reliability refers to the consistency of 
measurements among multiple examiners, while intra-examiner reproducibility is used for 
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the consistency of an individual examiner. Examiner reproducibility is expressed as a 
percentage of both exact agreement and agreement within ±1 mm between repeated 
measurements. Exact agreement detects the percentage of the time the examiner reports 
exactly the same measurement after repeated measurements. On the other hand, 
agreement within ±1 mm shows the percentage of the time the examiner’s repeated 
measurement is within ±1 mm of the initial. Polson recommended using a tolerance of ±1 
mm to calculate the percentage of reproducibility agreement in clinical periodontal 
examiner calibration data, while Best and colleagues reported that a change of 2 mm in 
attachment loss could be confirmed by a second examiner (Polson 1997, Best et al. 1990). 
Evaluating reproducibility for plaque and bleeding is difficult in calibration trials because 
the measurement process requires removal of plaque, while as far as bleeding is 
concerned, the first examination may affect the bleeding tendency during the second 
examination (Abbas et al. 1982).  
 
An initial calibration of the principal (GC) investigation (intra-examiner agreement) was 
performed with ten individuals: five periodontally healthy and five periodontitis patients. 
One quadrant of each patient was selected for examination and the assessment was 
repeated at least one week apart. Examination was performed with a manual periodontal 
probe (Michigan probe with Williams markings) at six sites per tooth (mesio-buccal, 
buccal, disto-buccal, mesio-lingual, lingual, and disto-lingual). The right maxillary quadrant 
and the left mandibular quadrant were randomly selected three times for the calibration, 
while the left maxillary quadrant and the right mandibular quadrant twice. The percentage 
of perfect agreement was calculated to be 81.4% for PPD and 79.8% for CAL. Agreement 
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with PPD ±1 mm was found in 100.0% of the sites and agreement with CAL ±2 mm in 
100.0% as well.  
 
The purpose of the calibration trial was to quantify intra- and inter-examiner reliability of 
measuring PPD and CAL. Six individuals recruited to serve in the calibration trial and were 
different than those utilized in the GCF study. They presented with a range of periodontal 
health and each examiner assessed PPD and CAL using a manual periodontal probe 
(Michigan probe with Williams markings) at six sites per tooth (mesio-buccal, buccal, disto-
buccal, mesio-lingual, lingual, and disto-lingual). Each examiner had one quadrant of teeth 
examined twice and he/she was blind to the previous measurement. Measuring single 
quadrants on multiple patients is preferred over multiple quadrants on one or two patients 
due to patient specific factors that may impact examiner’s reproducibility (Janssen and 
Faber 1988). One examiner performed all periodontal measurements for all four quadrants 
of each patient and served as the gold standard. For the intra-examiner variability, the first 
measurements were compared to the second measurements to report the percentage of 
exact agreement, agreement within ±1 mm for PPD and agreement within ±2 mm for CAL. 
For the inter-examiner variability, measurements of each examiner were compared to the 
measurements served as the gold standard. Similarly with the intra-examiner variability, 
exact agreement, agreement of PPD within ±1 mm and agreement of CAL within ±2 mm 
were calculated.  
 
The intra-examiner agreement of the principal (GC) investigator in the second calibration 
trial was 72.4% for perfect agreement in PPD, 70.5% perfect agreement in CAL, 100.0% 
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agreement with PPD ±1 mm and 100.0% agreement with CAL ±2 mm. The percentages 
of perfect agreement among all examiners ranged from 72.4% to 82.7% for PPD and from 
47.0% to 74.4% for CAL. The agreement between examiners with PPD ±1 mm ranged 
from 98.8% to 100.0%, while the agreement with CAL ±2 mm was between 98.2% to 
100.0%. Inter-examiner variability was tested between each examiners’ measurements 
and the gold standards’ measurements. The exact agreement in PPD varied from 46.0% 
to 63.0% and in CAL from 25.6% to 57.8%. Agreement in PPD within 1 mm ranged from 
92.1% to 99.4%, whereas agreement in CAL within 2 mm was determined to be between 
92.9% and 100.0%.  
 
Sample collection 
 
In each patient, up to four interproximal non-adjacent sites were selected for sampling 
after reviewing a patients full-mouth periodontal measurements. GCF sampling was 
performed either before full-mouth periodontal measurements or at least 2 weeks after the 
initial comprehensive examination. All subjects were positioned in the supine position in a 
dental chair. Before GCF sample collection, the supragingival plaque was removed from 
the interproximal surfaces that were planned to be sampled with a sterile hand instrument. 
A gentle stream of air was then directed parallel to the buccal and lingual surfaces without 
disturbing the gingival margin for approximately 3-5 seconds with the use of an air syringe. 
GCF samples were obtained one at a time using sterile paper strips (Periopaper). Paper 
strips were gently introduced into the gingival crevice until a mild resistance was felt. GCF 
collection time was 30 seconds for each strip. Samples that were contaminated with blood 
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or visible saliva were discarded. Immediately following GCF collection, the paper strip was 
placed into a previously calibrated electronic volume quantification unit (Periotron 6000) 
to determine the collected volume. Filter papers were immediately placed in 5.0 mL vials 
and kept on ice until the end of study visit. Samples were then transferred and stored at -
80oC until processing. All samples were collected by a single examiner (GC).  
 
In the chronic periodontitis group, GCF samples were collected from up to four 
interproximal non-adjacent sites. Diseased sites exhibited PPD  5 mm, CAL  4 mm and 
radiographic evidence of bone loss. Areas with the greatest inflammation, most significant 
PPD, CAL and radiographic bone loss were preferred for GCF sampling. When included 
individuals with chronic periodontitis exhibited healthy sites (PPD  4 mm, CAL  2 mm 
and no evidence of radiographic bone loss), up to two interproximal non-adjacent sites 
were selected for GCF sampling and the healthiest sites were preferred. In the 
periodontally healthy participants, samples were collected from up to four interproximal 
non-adjacent randomly selected sites with PPD  4 mm, CAL  2 mm and no evidence of 
radiographic bone loss 
 
Periotron calibration 
 
The following steps were performed, following the manufacturer’s instructions, to prepare 
a standard curve relating Periotron readings to volume of fluid in microliters.  
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1) A blank paper strip was inserted between the Periotron fluid meter sensors and the 
instrument was set to zero by turning the dial to the left or right. The blank strip was 
discarded once it was set to zero.  
2) Using a microliter syringe, 0.25 µL distilled water was carefully delivered to a paper strip 
and the strip was placed between the Periotron sensors. The Periotron score was 
recorded.  
3) Step 2 was repeated three more times with this volume (0.25 µL) and the average score 
was recorded.  
4) Using a microliter syringe, 0.50 µL distilled water was carefully delivered to a paper strip 
and the strip was placed between the Periotron sensors. The Periotron score was 
recorded. 
5) Step 4 was repeated three more times with this volume (0.50 µL) and the average score 
was recorded. 
6) Using a microliter syringe, 0.75 µL distilled water was carefully delivered to a paper strip 
and the strip was placed between the Periotron sensors. The Periotron score was 
recorded. 
7) Step 6 was repeated three more times with this volume (0.75 µL) and the average score 
was recorded. 
8) Using a microliter syringe, 1.0 µL distilled water was carefully delivered to a paper strip 
and the strip was placed between the Periotron sensors. The Periotron score was 
recorded. 
9) Step 8 was repeated three more times with this volume (1.0 µL) and the average score 
was recorded. 
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10) Using a microliter syringe, 1.25 µL distilled water was carefully delivered to a paper 
strip and the strip was placed between the Periotron sensors. The Periotron score was 
recorded. 
11) Step 10 was repeated three more times with this volume (1.25 µL) and the average 
score was recorded. 
 
Once scores were obtained for all known volumes, a standard curve relating the volume 
of fluid (µl) on the "x" axis to the Periotron score on the "y" axis was prepared. A 
mathematic equation (y=mx+b) that describes the volume of fluid and the Periotron score 
was determined based on the standard curve. Paper strips with the collected GCF 
samples from the study participants were placed between the sensors and a Petriotron 
score was automatically determined. The volume of GCF was determined by interpolation 
from the standard calibration curve utilizing the above mentioned equation.  
 
Assay methodologies 
 
GCF samples were analyzed by an enzyme-linked immunosorbent assay ELISA. Before 
the quantification of SOST, Wnt-5a and TNF-Į, GCF samples were removed from -80oC 
and remained in room temperature for 30 minutes. Then, GCF samples were eluted from 
the paper strips by placing them in 300 ȝL phosphate buffered saline (PBS) (pH 7.4). The 
tubes were vortexed and homogenized for 1 minute and then centrifuged at 3,000 rpms 
for 15 minutes at 4oC. The supernatants were collected. The total amounts of SOST, Wnt-
5a and TNF-Į in the samples were analyzed separately by sandwich ELISA using 
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commercially available kits. Procedures were performed according to the instructions of 
the manufacturers.  
 
SOST 
 
Initially all reagents were brought to room temperature for at least 30 minutes before use. 
A human SOST standard was reconstituted with distilled water (1 mL) producing a stock 
solution of 20,000 pg/mL. The standard was mixed to ensure complete reconstitution and 
it was allowed to sit for a minimum 30 minutes with gentle agitation prior to making any 
dilutions. Then, 900 ȝL of Callibrator Diluent RD5-20 Concentrate (concentrated buffered 
protein base with preservatives) were pipetted into a 2,000 pg/mL tube, and 500 pg/mL 
were pipetted into 7 other tubes. The stock solution of 20,000 pg/mL was used to produce 
a dilution series. More specifically, 100 ȝL of the stock solution was pipetted into the tube 
with 900 ȝL of Callibrator Diluent RD5-20 Concentrate to produce 2000 pg/mL of SOST. 
Then, 500 ȝL were transferred from this tube to the next one with 500 pg/mL of Callibrator 
Diluent RD5-20 Concentrate producing a concentration of 1,000 pg/mL of SOST. Similarly, 
tubes of 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.3 pg/mL and 0 pg/mL were 
produced. Each tube was mixed thoroughly before the next transfer. The 2,000 pg/mL of 
SOST standard served as the highest standard, while the last tube with only Callibrator 
Diluent RD5-20 Concentrate served as the zero standard (0 pg/mL).  
 
A total of 100 ȝL Assay Diluent RD1X (buffered protein base with preservatives) was 
added to each well in the microplate. Then, 50 ȝL of standard or sample were added per 
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well, covered with an adhesive strip and incubated for 2 hours at room temperature on a 
horizontal orbital microplate shaker. Wash buffer was prepared by adding 20 mL of Wash 
Buffer Concentrate (25-fold concentrated solution of buffered surfactant with 
preservatives) to distilled water to prepare 500 mL of wash buffer. Each well was aspirated 
and washed with 400 ȝL of Wash buffer for a total of 4 washes. Human SOST Conjugate 
200 ȝL (polyclonal antibody specific for human SOST conjugated to horseradish 
peroxidase with preservatives) was added to each well, covered with a new adhesive strip 
and incubated at room temperature on the shaker. After 2 hours of incubation, aspiration 
and four washes with 400 ȝL Buffer wash were performed. Stabilized hydrogen peroxide 
was mixed with stabilized chromogen (tetramethylbenzidine) in equal volumes and 200 ȝL 
of this solution was added to each well for a 30-minute incubation at room temperature 
protected from light. The assay was terminated with 50 ȝL of 2N sulfuric acid added to 
each well and the optical density was determined immediately using a microplate reader 
set to 450 nm with 570 nm wavelength correction. The minimum detectable limits of SOST, 
according to the manufacturer, ranged from 0.37 to 3.80 pg/mL with a mean value of 1.74 
pg/mL.  
 
Wnt-5a 
 
Initially, all reagents were brought to room temperature for at least 30 minutes before use. 
The standard was centrifuged at 10,000 rpms for 30 seconds at room temperature. This 
standard was then reconstituted with 1.0 mL sample diluent producing a stock solution of 
10 ng/mL and mixed to ensure complete reconstitution. It was allowed to sit for a minimum 
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of 15 minutes with gentle agitation prior to making dilutions. Sample diluent, 250 ȝL, was 
then pipetted into 7 tubes and using the stock solution, a 2-fold dilution series was 
produced. More specifically, 250 ȝL were transferred from one vial to another, while each 
tube was thoroughly mixed before the next transfer. The undiluted standard served as the 
highest standard (10 ng/mL), while the tube with only 250 ȝL sample diluent served as the 
zero standard (0 ng/mL).  
 
A total of 100 ȝL standard or sample was added per well and the microplate was covered 
with adhesive strip and incubated for 2 hours at 37oC. Biotin-antibody was centrifuged 
before opening and a 100-fold dilution was performed with Biotin-antibody diluent to 
produce Biotin-antibody (1x). Following the 2 hours of incubation, 100 ȝL of Biotin-
antibody (1x) was added to each well, then the microplate was covered with a new 
adhesive strip and incubated for 1 hour at 37oC. Wash buffer was prepared by adding 20 
ml of Wash Buffer Concentrate (25x) into distilled water to prepare 500 ml of Wash buffer 
(1x). Each well was aspirated and washed with 200 ȝL Wash buffer (1x) using a 
multichannel pipette for a total of three washes. HRP-avidin was centrifuged before 
opening and a 100-fold dilution was performed with HRP-avidin diluent to produce HRP-
avidin (1x). Following the washes, 100 ȝL of HRP-avidin (1x) was added to each well and 
then the microplate was covered again with a new adhesive strip and incubated for 1 hour 
at 37oC. Aspiration and washes with 200 ȝL of the Wash buffer were then made for a total 
of five times. TMB substrate 90 ȝL was finally added to each well for a final incubation for 
30 minutes at 37oC protected from light. The assay was terminated with 50 ȝL of 2N 
sulfuric acid added to each well and the optical density was determined immediately using 
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a microplate reader set to 450 nm with a 570 nm wavelength correction. The detection of 
Wnt-5a, according to the manufacturer, ranged from 0.156 to 10 ng/mL with a minimum 
detectable dose of less than 0.039 ng/mL.  
 
TNF-Į 
 
Initially all reagents were brought to room temperature for at least 30 minutes before use. 
The standard was then reconstituted with 1.0 mL sample diluent producing a stock solution 
of 300 pg/mL and mixed to ensure complete reconstitution. It was allowed to sit for a 
minimum of 10 minutes with gentle agitation prior to making dilutions. The stock solution 
was first diluted to 100 pg/mL and the diluted standard served as the highest standard 
(100 pg/mL). Sample diluent 500 ȝL was then pipetted into 7 tubes and using the stock 
solution, a 2-fold dilution series was produced. More specifically, 500 ȝL were transferred 
from one vial to another, while each tube was thoroughly mixed before the next transfer. 
The last tube with only 500 ȝL sample diluent served as the zero standard (0 pg/mL).  
 
A total of 100 ȝL of the standard or sample were added per well and the microplate was 
covered with adhesive strip and incubated for 1 hour at 37oC. Detection A was centrifuged 
before opening and a 100-fold dilution was performed with Assay Diluent A to produce 
Detection Reagent A. Following the 1 hour of incubation, 100 ȝL of Detection Reagent A 
was added to each well, then the microplate was covered with a new adhesive strip and 
incubated for 1 hour at 37oC. Wash buffer was prepared by adding 20 ml of Wash Buffer 
Concentrate (30x) into distilled water to prepare 600 ml of Wash buffer (1x). Each well 
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was aspirated and washed with 350 ȝL Wash buffer (1x) using a multichannel pipette for 
a total of three washes. Detection B was centrifuged before opening and a 100-fold dilution 
was performed with Assay Diluent B to produce Detection Reagent B. Following the 
washes, 100 ȝL of Detection Reagent B was added to each well and then the microplate 
was covered again with a new adhesive strip and incubated for 30 minutes at 37oC. 
Aspiration and washes with 350 ȝL of the Wash buffer were then made for a total of five 
times. TMB substrate 90 ȝL was finally added to each well for a final incubation for 20 
minutes at 37oC protected from light. The assay was terminated with 50 ȝL of 2N sulfuric 
acid added to each well and the optical density was determined immediately using a 
microplate reader set to 450 nm. The detection of TNF-Į, according to the manufacturer, 
ranged from 1.56 to 100 pg/mL with a minimum detectable dose of less than 0.52 pg/mL.  
 
Analysis of GCF levels and concentration 
 
The levels of SOST, Wnt-5a and TNF-Į in each sample were extrapolated from the known 
quantities on the standard curve of each ELISA plate based on the dilutions. The results 
were expressed as the total amount in 30 seconds and the concentration in the GCF 
sample. Calculation of the concentration data was performed by dividing the amount of 
each protein by the volume of the sample as determined by the standard curve of the 
volume of fluid and the Periotron score. Total values of SOST and TNF-Į were measured 
in pg, while total values of Wnt-5a were expressed in ng. Values of concentrations of 
SOST and TNF-Į were presented as pg/ȝL, whereas Wnt-5a concentration was 
expressed in ng/mL.  
58 
 
Sample size calculation 
 
The primary outcome variables (GCF levels of SOST and Wnt-5a) were used to decide 
the sample size calculation and determine the power of the study. Due to lack of available 
information in the literature surrounding GCF levels of SOST and Wnt-5a in chronic 
periodontitis and periodontally healthy patients, no sample calculation could be performed. 
A pilot study was initially conducted including five periodontitis patients and five healthy 
control individuals in order to determine the sample size of this research. We estimated 
that a sample size of 22 patients per group would allow for a type II error level of ȕ=0.05 
(95% power) and a type I error level of Į=0.05 (5% probability). To account for possible 
complications with the GCF samples, a total of 25 patients in each group were included.  
 
Sample size determination is an important parameter in planning an epidemiological 
study. An adequate sample size ensures that the study will show reliable information 
regardless of the results from the statistical analysis (e.g whether the ultimate data 
suggest a statistically significant difference or not). Sample size is the number of subjects 
in a group under investigation. The larger the sample size, the greater the precision and 
therefore the power to detect an effect of a given size. In contrast, if a very large sample 
is used, then even small differences from the null hypothesis will be statistically significant, 
even if these are not clinically relevant.  
 
Power-based sample size calculations relate to hypothesis testing. It depends on the null 
hypothesis, the significance level, type I and type II errors. The null is that there is no 
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difference between the two groups. The statistical analysis of the study will demonstrate 
either sufficient evidence to reject the null or not enough evidence to reject the null 
hypothesis. There are four possible outcomes performing a statistical hypothesis that 
depend on whether the null hypothesis is true or false and whether the examiner decides 
to reject or retain it. When the null hypothesis is true, the probability of making a type I 
error is called alpha (Į). Type I error is the incorrect rejection of the null hypothesis or in 
other words when the statistical analysis reveals a significant difference when there is not 
really a difference. It is also called a “false positive” finding. When the null hypothesis is 
false, the probability of making a type II error is called beta (ȕ). Type II error is the incorrect 
retention of a false null hypothesis, or in other words when the statistical analysis shows 
non-significant results when there is really a significant effect. This may be attributed to 
inadequate power and/or sampling error. Type II error is also called “false-negative” 
finding. The statistical power is the probability of not missing a significant effect due to 
sampling error when there is an effect.  
 
The general formula for sample size calculation for two groups using a continuous 
outcome is:  
 ܰ ݌݁ݎ ݃ݎ݋ݑ݌ ൌ  ʹ ൈ ሺܼܽ ൅ ܼߚሻଶ ݀ଶ  
 
Where d is the effect size.  
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Effect size is defined as the difference between the means for the two groups, divided by 
an estimate of the standard deviation in the population. The effect side d can be calculated 
using the following formula:  
 ݀ ൌ ݔଵതതത െ  ݔଶതതതܵ௣௢௢௟௘ௗ  
 
The estimate of the standard deviation in the population can be calculated from the 
following formula:  
 
ܵ௣௢௢௟௘ௗ ൌ ඨሺ݊ଵ െ ͳሻݏଵଶ ൅ ሺ݊ଶ െ ͳሻݏଶଶ݊ଵ ൅ ݊ଶ െ ʹ  
 
Therefore, the number needed per group is proportional to the square of the standard 
deviation and inversely proportional to the square of differences between the two groups 
(delta). The more variability (standard deviation), the larger the sample that is needed, 
while the greater the true difference between the groups, the smaller the sample size.  
 
ܰ ݌݁ݎ ݃ݎ݋ݑ݌ ൌ   ʹ ൈ ݏ௣௢௢௟௘ௗଶ  ൈ  ሺܼܽ ൅ ܼߚሻଶ ݈݀݁ݐܽଶ  
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Statistical analysis 
 
Descriptive statistics were used to present the results of the sample’s characteristics 
including mean and standard deviation for age, number of teeth, periodontal parameters 
and GCF protein levels, while counts and percentages were used for categorical variables 
such as gender, race and smoking history. The Shapiro-Wilk test was used to determine 
whether the data were normally distributed. Normal is used to describe a symmetrical, 
bell-shaped curve, which exhibits the greatest frequency of scores in the middle, close to 
the mean value. The null hypothesis of this test is that the population is normally 
distributed. Therefore, if the p-value is less than the significance level, then the null 
hypothesis is rejected and there is evidence that the data tested are not normally 
distributed. In this study, the null hypothesis was rejected because p<0.001 suggesting 
violation of the assumption of normality. The Shapiro-Wilk test statistic W is defined as the 
ratio of two estimates of the variance of the sample: 
ܹ ൌ  σ ܽ௜௡௜ୀଵ  ݔ௜ଶσ  ሺݔ௜௡௜ୀଵ െݔҧሻଶ 
 
where 
• ݔҧ ൌ  σ ௫೔೙೔సభ௡  is the sample mean.  
• xi is the order statistic, implying that the data sample must be 
sorted in increasing values (x1, x2, …, xn) 
• Įi is the Shapiro-Wilk coefficients 
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Non-parametric comparisons were therefore performed. A Mann–Whitney U test was used 
to compare protein total amounts and concentrations between healthy patient sites and 
diseased sites in periodontitis patients. A Wilcoxon signed-rank test was utilized to 
compare diseased sites and healthy sites in a subset of periodontitis patients that 
exhibited both diseased and healthy sites. The Spearman’s rank correlation test was used 
to detect the relationship between GCF total amounts and concentrations of SOST, Wnt-
5a and TNF-Į with the periodontal clinical parameters including PPD (full-mouth and 
sampled sites), CAL (full-mouth and sampled sites), percentage of sites with PPD = 1-3 
mm, PPD = 4-6 mm, PPD ≥ 7 mm, CAL = 0-2 mm, CAL = 3-4 mm and CAL ≥ 5 mm as 
well as the patient’s age. Receiver operating characteristic (ROC) curves were 
constructed for the total amounts of SOST, Wnt-5a and TNF-Į of healthy and periodontitis 
groups. The area under the curve and the 95% confidence intervals were computed for 
each protein. All data were analyzed with SPSS v24 (SPSS Inc. IMB, USA) or SAS v9.3 
(SAS Institute Inc., Cary, NC, USA). P-values less than 0.05 were considered statistically 
significant. Graphing was performed with GraphPad Prism software. 
 
Mann-Whitney U test 
 
The Mann-Whitney U test is used to compare differences between two independent 
groups when the dependent variable is either ordinal or continuous, but not normally 
distributed. It is the non-parametric alternative to the independent t-test and tests the null 
hypothesis that the distributions of both populations are equal. Calculation of the Mann-
Whitney U test can be performed using the following formula:  
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 ܷ ൌ ଵܷ ൅ ଶܷ 
 
where 
ଵܷ ൌ ܴଵ െ  ݊ଵሺ݊ଵ ൅ ͳሻʹ  
and  
ଶܷ ൌ ܴଶ െ  ݊ଶሺ݊ଶ ൅ ͳሻʹ  
 
n1 and n2 are the sample sizes for sample 1 and 2 
R1 and R2 are the sum of the ranks in sample 1 and 2. Each observation is assigned to a 
rank, i.e. 1 to the smallest observation, 2 to the second smallest observation etc.  
 
Therefore, the following formula is used: 
 
ܷ ൌ ݊ଵ݊ଶ ൅ ݊ଶ  ሺ݊ଶ ൅ ͳሻʹ െ ෍ ܴ௜௡మ௜ୀ௡భାଵ  
 
where  
n1: sample size of sample 1 
n2: sample size of sample 2 
Ri: rank of the sample size 
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Wilcoxon signed-rank test 
 
The Wilcoxon signed-rank test is used to compare differences between two related 
samples, either matched items or repeated measurements of the same sample that are 
not normally distributed. It is the non-parametric alternative to the paired t-test and tests 
the null hypothesis that the distributions of two dependent populations are equal. For each 
item in a sample the test obtains an absolute difference score between two 
measurements. Calculation of the Wilcoxon signed-rank test can be performed using the 
following formula for large samples:  
 ܼ ൌ ܹ െ ߤௐߪௐ  
 
where the test statistic W is obtained as the sum of the positive ranks (the absolute 
difference between the pair of values): 
 
ܹ ൌ ෍ ܴ௜ሺାሻ௡௜ୀଵ  
 
and  
 ߤௐ ൌ ݊ ሺ݊ ൅ ͳሻͶ  
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and  
ߪௐ ൌ  ඨ݊ ሺ݊ ൅ ͳሻሺʹ݊ ൅ ͳሻʹͶ  
 
with n being the sample size, i.e. the number of pairs.  
 
Z is then tested against the standard normal deviate zcritical. The null hypothesis is rejected 
if |Z| > zcritical.  
 
Spearman’s rank correlation test 
 
The Spearman’s rank correlation test is a non-parametric measure of rank correlation, the 
alternative of the Pearson correlation coefficient. It measures the strength and direction of 
the monotonic association between two ranked variables. A monotonic relationship is one 
that either never increases or never decreases as its independent variable increases. It 
can range from -1, which shows strong negative correlation, to +1, which demonstrates 
strong positive correlation.  
 
Calculation of the Spearman’s rank correlation test can be performed using the following 
formula for data that do not have tied ranks (data that have different values):  
 
ߩ ൌ ͳ െ ͸ σ ݀௜ଶ݊ሺ݊ଶ െ ͳሻ  
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where  
di: the difference in paired ranks (difference between the two ranks of each observation) 
n: the number of cases  
Calculation of the Spearman’s rank correlation test can be performed using the following 
formula for data with tied ranks (data that have the same value):  
 ߩ ൌ σ ሺݔ௜ െ ݔҧሻሺݕ௜ െ ݕതሻ௜ඥσ ሺݔ௜ െ ݔҧሻଶ௜  σ ሺݕ௜ െ ݕതሻଶ௜    
where 
i: paired score  
 
 
ROC curve  
 
The receiver operating characteristic (ROC) curve is a fundamental tool for diagnostic test 
evaluation. The true positive (sensitivity) is plotted against the false positive rate (1-
specificity) for all possible cutoff values. Each point represents a value with a specific 
sensitivity and specificity. The area under the ROC curve is a measure of the accuracy of 
a diagnostic test. It is a measure of how well a parameter can distinguish between two 
diagnostic groups (disease and health) in a diagnostic test. The higher the area under the 
curve (AUC) values, the better test performance. The AUC values can range from 0.5 (no 
diagnostic value) to 1.0 (excellent diagnostic value). P-value tests the null hypothesis that 
the area under the curve really equals 0.50.  
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RESULTS 
 
Demographic characteristics 
 
The demographic characteristics of the total population as well as the periodontitis and 
healthy groups are shown in Table 1. The total population of the study consisted of 50 
patients with a mean age of 43.4 ± 18.5 years. Twenty-five individuals diagnosed with 
chronic periodontal disease were included in the periodontitis group (50%), while the 
healthy group consisted of 25 subjects with a healthy periodontium (50%). A statistically 
significant difference was detected in regards to the mean age of the participants in the 
periodontitis and healthy groups (p < 0.001). More specifically, patients diagnosed with 
chronic periodontitis were 57.9 ± 12.6 years old, whereas healthy individuals were 
significantly younger and had a mean age of 28.9 ± 10.2 years. No significant differences 
were observed between the two groups with respect to gender (p=0.077) and race 
(p=0.070). In total, 18 (36.0%) males and 32 (64.0%) females participated in this cross-
sectional study and the majority of the individuals were Caucasians (40%). Most of the 
participants in both periodontitis and healthy groups were females and Caucasians, while 
Asians presented only in the healthy group (4%) and Hispanics only in the periodontitis 
group (4%). Smoking status was recorded as never smokers, ex-smokers and current 
smokers. Smoking history was significantly different (p < 0.001) between the two groups 
with current smokers (n=9, 18%) and ex-smokers (n=6, 12%) being only in the 
periodontitis group, while never smokers were only included in the healthy group (n=25, 
50%). Current smoking was reported by 18% of the total population and all of them self-
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reported cigarette smoking. The frequency of smoking was reported as <10 cigarettes/day 
by 55.5%, 10-20 cigarettes/day by 44.4% and >20 cigarettes/day by 11.1%. The mean 
duration of smoking was 30.8 years with a range from 20 to 55 years.  
 
Periodontal status 
 
The periodontal status of the total population as well as the periodontitis and healthy 
groups are presented in Table 2. The periodontal status of the periodontitis group was 
statistically significantly worse than in the healthy group as expressed by the significantly 
different clinical periodontal measures. More specifically, the periodontitis group exhibited 
significantly higher mean values of PPD (p < 0.001), CAL (p < 0.001), BOP (p < 0.001), 
PI (p = 0.001), missing teeth (p < 0.001), PPD = 4-6 mm (p < 0.001), PPD ≥ 7 mm (p = 
0.002), CAL = 3-4 mm (p < 0.001) and CAL ≥ 7 mm (p < 0.001) than the healthy group. 
On the contrary, the healthy group showed statistically significantly higher mean values of 
PPD = 1-3 mm (p < 0.001) and CAL = 0-2 mm (p < 0.001) than the periodontitis group.  
 
Sampled sites were divided into three groups: diseased sites in periodontitis patients, 
healthy sites in periodontitis patients and healthy sites in healthy patients. The PPD and 
CAL of the sampled sites in healthy and periodontitis groups are shown in Table 3. 
Diseased sites in periodontitis patients were associated with higher PPD and CAL than 
healthy sites in periodontitis and healthy patients. The BOP of the sampled sites in healthy 
and periodontitis groups is presented in Table 4. In general, diseased sites in the 
periodontitis group exhibited a higher frequency of BOP than healthy sites in periodontitis 
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and healthy individuals. Ninety-two percent of the sampled diseased sites showed BOP, 
while the majority of the healthy sites in periodontitis patients (78.6%) and the healthy sites 
in periodontally healthy patients (20.0%) demonstrated absence of BOP. Healthy sampled 
sites from the periodontitis and healthy groups exhibited a similar periodontal status. 
 
Protein levels and concentrations of periodontitis and heathy patients  
 
The protein levels and concentrations of SOST, Wnt-5a and TNF-Į of periodontitis and 
healthy patients are reported in Table 5. The protein levels of SOST, Wnt-5a and TNF-Į 
were similar between the two groups (p > 0.05). More specifically, the median of SOST 
was slightly higher in the periodontitis group (135.5 pg) when compared to the healthy 
group (117.9 pg) without reaching statistically significance (p = 0.068). The median of Wnt-
5a found to be 1.9 ng for the periodontitis patients which was lower but statistically 
insignificant (p = 0.854) in comparison to the median of the healthy patients (2.4 pg). 
Similarly, the healthy group showed an insignificantly (p = 0.071) higher median value of 
TNF-Į (40.3 pg) when compared to the periodontitis group (27.2 pg). The distributions of 
the total amounts of GCF SOST, Wnt-5a and TNF-Į in the periodontitis and healthy groups 
are presented in Figures 8, 9 and 10 with no significant differences found between the 
chronic periodontitis and periodontally healthy groups (p > 0.05).  
 
When the data were expressed as concentration, significant differences were found 
among the study groups (p < 0.05). Periodontally healthy individuals showed statistically 
significantly higher concentration of SOST (p < 0.001), Wnt-5a (p = 0.003) and TNF-Į (p 
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< 0.001) compared to the periodontitis patients. However, the results obtained based on 
the concentrations should be interpreted with caution due to the increased variability as 
expressed by the range and the standard deviation. The distributions of the concentrations 
of GCF SOST, Wnt-5a and TNF-Į in the periodontitis and healthy groups are presented 
in Figures 11(a, b), 12 and 13. 
 
The protein levels and concentrations of SOST, Wnt-5a and TNF-Į at diseased and 
healthy sites in a subset of the periodontitis patients that exhibited both diseased and 
healthy sites are reported in Table 6. Significant differences were found among the 
sampled sites in the periodontitis group in regards to the total protein levels of Wnt-5a. 
More specifically, the diseased sites exhibited a median Wnt-5a value of 1.6 ng which was 
statistically significantly higher (p = 0.017) than the median Wnt-5a of the healthy sites 
(1.1 ng). The protein levels of SOST and TNF-Į in the GCF of healthy and periodontitis 
sites were similar (SOST: 135.5 pg at diseased versus 138.8 pg at healthy sites; TNF-Į: 
21.9 pg at diseased versus 17.7 pg at healthy sites) and the significant level was not 
reached (p > 0.05). Diseased sites showed a slightly higher level of TNF-Į than the healthy 
sites (p = 0.194), while the opposite was found for SOST (p = 0.413) but no significant 
differences were found. The distributions of the total amounts of GCF SOST, Wnt-5a and 
TNF-Į of the diseased and healthy sites are shown in Figure 14, 15 and 16.  
 
With respect to concentrations, SOST, Wnt-5a and TNF-Į were statistically significantly 
different between the two examined groups. Similarly with the results from the comparison 
between periodontitis and healthy patients, healthy sites demonstrated statistically 
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significantly higher concentrations of SOST (p = 0.001), Wnt-5a (p = 0.001) and TNF-Į (p 
= 0.001) when compared to diseased sites. Although the level of significance was reached, 
the variability present in the sampled sites impact the ability to draw conclusions based on 
these findings. The distributions of the concentrations of GCF SOST, Wnt-5a and TNF-Į 
of the diseased and healthy sites are demonstrated in Figure 17, 18 (a, b) and 19.  
 
Correlations 
 
The Spearman’s rank correlations (rho) between protein total levels of SOST, Wnt-5a and 
TNF-Į with the periodontal clinical and age parameters are shown in Table 7. A statistically 
significant positive correlation was found between the total amounts of SOST with full-
mouth PPD (r = 0.29, p = 0.044), full-mouth CAL (r = 0.36, p = 0.010), PPD of the sampled 
sites (r=0.30, p=0.037) and PPD = 4-6 mm (r = 0.33, p = 0.018). In addition, a statistically 
significant negative correlation was detected with the percentage of sites with PPD = 1-3 
mm and the total amounts of SOST (r = -0.34, p = 0.017). A trend towards negative 
correlation was observed with CAL = 0-2 mm (r = -0.28, p = 0.052), while a trend towards 
positive correlation was found with age (r = 0.27, p = 0.055). The total amounts of Wnt-5a 
were not statistically significantly associated with any of the examined parameters (p > 
0.05). When the protein levels of TNF-Į were examined, a statistically significant negative 
correlation was noted with the PPD of the sampled sites (r = -0.29, p = 0.039). A trend 
towards negative correlation was also observed between the total amount of TNF-Į with 
age (r = -0.28, p = 0.052).  
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The Spearman’s rank correlations (rho) between concentrations of SOST, Wnt-5a and 
TNF-Į with the periodontal clinical and age parameters are shown in Table 8. Statistically 
significantly correlations were found between the concentrations of SOST, Wnt-5a and 
TNF-Į with all examined parameters. In particular, statistically significant negative 
correlations were detected between full-mouth PPD, full-mouth CAL, PPD of the sampled 
sites, CAL of the sampled sites, PPD = 4-6 mm, PPD ≥ 7 mm, CAL = 3-4 mm, CAL ≥ 5 
mm and age with the concentrations of SOST, Wnt-5a and TNF-Į (p-values range from < 
0.001 to 0.016). Moreover, statistically significant positive correlations were observed 
between the healthy periodontal parameters, PPD = 1-3 mm and CAL = 0-2 mm, with the 
concentrations of SOST, Wnt-5a and TNF-Į (p-values range from < 0.001 to 0.015). 
 
ROC analyses for diagnostic value 
 
ROC analyses of the total amounts of GCF SOST, Wnt-5a and TNF-Į were performed to 
diagnose chronic periodontitis. ROC analysis of total amounts of GCF SOST to diagnose 
chronic periodontitis is shown in Figure 20. The area under the ROC curve for GCF SOST 
was 0.652, the 95% confidence interval was 0.490 and 0.814 and the p-value was 0.065. 
ROC analysis of total amounts of GCF Wnt-5a to diagnose chronic periodontitis is shown 
in Figure 21. The area under the ROC curve for GCF Wnt-5a was 0.516 with 95% 
confidence interval between 0.348 and 0.684 with a non-significant p-value of 0.846. In 
regards to TNF-Į, ROC analysis of total amounts of GCF TNF-Į to diagnose chronic 
periodontitis is shown in Figure 22. The area under the ROC curve was found to be 0.642 
with 95% confidence interval from 0.485 to 0.798 and a corresponding p-value of 0.086. 
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In general, protein levels of GCF SOST, Wnt-5a and TNF-Į showed low discriminatory 
ability to diagnose chronic periodontitis and periodontal health.  
 
Additional analyses 
 
The protein total levels of SOST, Wnt-5a and TNF-Į in sites with presence and absence 
of bleeding on probing are demonstrated in Table 9. Sites with bleeding on probing 
exhibited statistically significantly higher median levels of SOST when compared to sites 
without bleeding on probing (p = 0.035). On the contrary, the median protein levels of Wnt-
5a (p = 0.265) and TNF-Į (p = 0.194) were not associated with the presence or absence 
of bleeding on probing in the sampled sites.  
 
Protein total levels and concentrations of SOST, Wnt-5a and TNF-Į between males and 
females are shown in Table 10. Males showed statistically significantly higher median 
Wnt-5a levels than females (p = 0.031), while no differences were found between the 
groups in regards to total SOST levels (p = 0.642) and TNF-Į levels (p = 0.777) as well 
as the concentrations of SOST (p = 0.166), Wnt-5a (p = 0.307) and TNF-Į (p = 0.709).  
 
“Strict” criteria for patient selection based on clinical periodontal 
parameters  
 
An additional analysis was performed including patients with a more “strict” definition of 
periodontal disease and health. In this analysis, patients with a generalized form of 
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periodontitis in at least γ0% of the sites with PPD ≥ 4 mm, CAL ≥ γ mm and presence of 
BOP were included in a new periodontitis subgroup. In this separate analysis, patients 
were considered periodontally healthy when PPD ranged from 1 to γ mm, CAL ≤ 1 mm 
and BOP ≤ 15%. Ten patients from the initial population met the “strict” periodontitis 
criteria, while ten individuals from the initial healthy group were eligible for the “strict” 
healthy subgroup. The Shapiro-Wilk test was also utilized to assess the normality of the 
distribution and nonparametric comparisons were performed. The protein levels of SOST, 
Wnt-5a and TNF-Į of periodontitis and healthy subgroups using “strict” criteria for 
diagnosing periodontal disease and health are shown in Table 11. Periodontitis subgroup 
exhibited higher median total amounts of SOST (140.0 pg), Wnt-5a (2.4 ng) and TNF-Į 
(44.7 pg) when compared to the healthy subgroup: 78.9 pg for SOST, 1.29 ng for Wnt-5a 
and 27.3 pg for TNF-Į. Statistical significance was reached for the comparison between 
the periodontitis and healthy subgroups in regards to the SOST total amounts (p = 0.002). 
Mann-Whitney U tests did not reach the significant level for Wnt-5a (p = 0.075) and TNF-
Į (p = 0.226). The distributions of the total amounts of GCF SOST, Wnt-5a and TNF-Į of 
the diseased and healthy sites in the strictly diagnosed periodontitis and healthy patients 
are presented in Figures 23, 24 and 25.  
 
ROC analyses of the total amounts of GCF SOST, Wnt-5a and TNF-Į were also 
performed to diagnose generalized chronic periodontitis using the data from the sample 
of the 20 strictly diagnosed periodontitis and healthy patients. The ROC curves are shown 
in Figure 26, 27 and 28. The area under the curve for SOST was estimated to be 0.900 
with a 95% confidence interval between 0.742 and 1.000. Protein total levels of SOST in 
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GCF discriminate between generalized periodontitis and health with a p-value of 0.002. 
When the total amounts of Wnt-5a were used to predict periodontal disease, the area 
under the curve was 0.740 (95% CI: 0.517-0.963) with a p-value of 0.070. With respect to 
TNF-Į, the area under the curve was found to be 0.660 (95% CI: 0.387-0.933) with a p-
value of 0.226.  
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DISCUSSION 
 
The use of GCF samples aims to develop an accurate, sensitive and reproducible method 
of detecting the presence of periodontal disease and to predict the risk of future 
periodontal destruction. Although clinical measures have been utilized extensively in 
everyday clinical practice and the combination of clinical and radiographic examination 
remains the gold standard in clinical periodontology and periodontal research, these 
diagnostic methods are time-consuming and proper training and calibration of the 
examiner is needed. Clinical measures provide a history of periodontal breakdown that 
already has occurred. When it comes to future periodontal destruction, biomarkers can 
detect early disease activity or risk of disease progression which will ultimately result in 
earlier therapeutic intervention. However, a significant association has to be initially found 
in a cross-sectional manner to establish a diagnostic use prior to evaluating it for a 
potential prognostic value. The present study intended to assess the involvement of Wnt 
signaling in chronic periodontitis and to examine whether SOST and Wnt-5a in the GCF 
has the potential to be used as diagnostic markers of periodontal disease status. We 
hypothesized that sites with chronic periodontitis exhibit elevated protein levels and 
concentrations of SOST, Wnt-5a and TNF-Į when compared to periodontally healthy 
sites. In addition, a positive correlation between the examined periodontal clinical 
parameters including probing pocket depth and clinical attachment loss were expected to 
be found with the total amounts and concentrations of SOST, Wnt-5a and TNF-Į in GCF.  
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A number of sampling methods and collection times have been utilized in previous GCF 
studies. The method of collection and analysis significantly affects the quantity and quality 
of GCF samples revealing the need for standardization (Egelberg and Attstrom 1973, 
Persson and Page 1990, Lamster et al. 1989). Different sampling techniques, sampling 
times and data presentations are critical in GCF studies (Ozkavaf et al. 2000). In the 
present study, sampling was performed exclusively with paper strips using the same Lot 
number from a single manufacturer to avoid differences in the collected volume of the 
samples. A standardized time for collection of GCF was also applied to all sampled sites 
and it was set to 30 seconds. Immediate freezing of all samples was completed to prevent 
proteolysis and presentation of data was similarly presented for all samples. Sampled sites 
in the subjects with periodontitis demonstrated PPD between 5 and 12 mm and CAL from 
4 to 13 mm. Sites were selected based on the most severe periodontal status. The 
increased variability in the periodontal status of the sampled sites may be considered a 
limitation of the study. GCF variability in regards to volume, concentration and total 
amounts are reported in the literature. It is believed that this variability may be associated 
with the current disease activity, progression of periodontal disease, the different stages 
of inflammation, disease severity as well as the microbial background (Goodson 2003, 
Griffiths 2003, Hancock et al. 1979). 
 
The expression of GCF data is presented both in total amounts and concentrations. 
However, the conclusions of the present study are primarily based on the total amount per 
standardized sampling time instead of concentration to eliminate the possible inherent 
errors in reporting concentrations. It has been shown that expressing molecules in GCF 
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as total amounts is more sensitive than reporting them as a concentration (Lamster 1997). 
An accurate calculation of proteins in GCF is impeded by the inability to determine the 
precise volume of small quantities of GCF that are usually recovered from healthy 
periodontal tissues (Lamster et al. 1985). A standard amount of GCF has to be collected 
in order to express accurately the results as concentrations. In addition, there are other 
parameters that may affect the concentration of GCF components. Greater GCF volume 
has been demonstrated at mandibular than maxillary sites (Smith and Gaegan 1991) as 
well as at posterior when compared to anterior sites in both periodontal health and disease 
(Smith 1992). When GCF levels are expressed in total amount per site, the differences 
are less pronounced and more closely associated with the severity or status of periodontal 
disease than when concentrations are used (Smith 1992). The quantity of saliva collected 
on filter paper strips has the potential to affect the GCF volume, while this does not 
significantly increase the amount of protein level per sample. Therefore, in studies 
including GCF data, drawing conclusions based on the total activity is more appropriate 
than concentrations (Lamster et al. 1986). 
 
Saliva and dental plaque are both possible contaminants of GCF (Griffiths et al. 1992). 
Dental plaque adhering to paper strips may lead to higher Periotron readings and therefore 
to a higher GCF volume (Stoller et al. 1990). In a study by Stoller and colleagues a 50% 
greater volume of GCF was detected when plaque was not removed from the teeth before 
sampling (Stoller et al. 1990). Similarly, Griffiths et al. (1992) showed that if visible plaque 
was left intentionally on a tooth, there was a consistent increase in GCF volume as the 
plaque accumulation was increased in the paper strip. Saliva may also increase the 
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estimated GCF volume as well as the flow rate as a result of the 82% of water that is 
contained in saliva (Stoller et al. 1990, Griffiths et al. 1992). To limit the effect of plaque 
on GCF volume in the present investigation, plaque removal prior to GCF sampling was 
performed, while teeth and surrounding periodontal tissues were dried to avoid 
contamination of GCF with saliva.  
 
Bone metabolism to maintain a healthy skeleton is controlled by osteoblasts and 
osteoclasts. SOST decreases osteoblastogenesis and osteoblastic activity antagonizing 
the Wnt signaling pathway (Li et al. 2005, Rossini et al. 2013). SOST also promotes 
osteoclast differentiation and bone resorption (Wijenayaka et al. 2011), while treatment 
with monoclonal antibodies targeting SOST have shown enhanced bone formation, 
increase bone mass and bone strength (Li et al. 2009, Li et al. 2010). In a cross-sectional 
study with peri-implantitis, peri-implant mucositis and healthy peri-implant tissues, 
crevicular fluid samples were collected and the concentrations of SOST were evaluated 
(Rakic et al. 2014).  SOST showed significantly increased levels in peri-implantitis tissues 
when compared to peri-implant mucositis and healthy tissues suggesting a potential role 
as a diagnostic marker of peri-implant destruction (Rakic et al. 2014). Another cross-
sectional study explored the involvement of SOST in chronic periodontitis (Napimoga et 
al. 2014). In this study, gingival biopsies and serum were sampled from systemically 
healthy patients diagnosed with chronic periodontitis and periodontally healthy patients. 
SOST was statistically significantly upregulated in the gingival tissue and serum samples 
of patients with chronic periodontitis when compared to periodontally healthy patients. 
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The involvement of SOST in periodontal destruction has also been supported by a study 
in rats in which inhibition of SOST with neutralized antibodies stimulated regeneration of 
the lost alveolar bone (Taut et al. 2013). Chronic periodontitis patients have also shown 
increased SOST levels in GCF in another prospective cohort study from Turkey (Balli et 
al. 2015). This study followed 54 patients with chronic periodontitis and periodontal health 
for 6 weeks after non-surgical periodontal therapy when GCF samples were collected and 
clinical examinations were performed. Non-surgical periodontal therapy resulted in 
decreased levels of SOST and its reduction was related to clinical improvement of a 
patient’s periodontal status. In the present study, statistically significant correlations were 
identified between the total amounts of SOST and clinical parameters when expressed as 
full-mouth and site-specific measures (p < 0.05). The total amount of SOST was slightly 
greater in the periodontitis group (135.5 pg) when compared to the healthy group (117.9 
pg), while no statistically significant difference was found (p>0.05). When diseased and 
healthy sites in a subset of periodontitis patients were examined, non-significant results 
were also found. Although both results from our investigation and the study of Balli et al. 
used GCF samples, the findings are not in complete agreement. This may be attributed to 
differences in the inclusion criteria. More specifically, in the present investigation, the 
absence of gingival inflammation was not required for the healthy group, while Balli and 
co-investigators restricted their GCF sample to healthy patients with a gingival index of 
zero. In addition, the periodontitis group, Balli and colleagues recruited patients with more 
generalized disease (bone loss affecting >30% of the existing teeth), while the range of 
PPD and CAL was narrower than in our investigation. Furthermore, another explanation 
could be the difference in the age of the patients in the periodontitis group. Our disease 
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group had a mean age of 57.9 years, whereas the previous study included a much younger 
group which demonstrated a mean age of 39.56 years. It is possible that cases of 
aggressive periodontitis may have been included in the study of Balli and colleagues 
(2015). Differences in the study methodology also included the sampled sites and the 
analysis process. In particular, in the present study both single- and multi-rooted teeth 
were sampled and each sample was analyzed separately which is in contrast with the 
Balli’s study that included only single-rooted teeth and the samples were pooled.  
 
Wnt-5a suppresses bone formation by enhancing RANKL-induced osteoclastogenesis 
and its up-regulated secretion may also enhance the expression of inflammatory-related 
genes through a novel NF-kappaB-dependent regulation (Maeda et al. 2007, Zhao et al. 
2015). Wnt-5a is secreted in chronic inflamed sites such as inflammatory synoviocytes. 
Nanbara et al. (2012) showed that Wnt-5a mRNA production is strongly induced by P. 
gingivalis LPS. In the same study, Wnt-5a mRNA was significantly up-regulated in chronic 
periodontitis gingival tissues as compared to healthy control tissues as a result of the 
periodontopathic bacteria (Nanbara et al. 2012). Similarly, a statistically significantly 
higher expression of Wnt-5a mRNA was found in gingival tissues from periodontally 
involved individuals when compared to healthy controls by a different research group 
(Maekawa et al. 2017). Although an increase Wnt-5a mRNA expression was found in 
periodontitis in comparison to health, this difference was not reflected at the protein level 
(Maekawa et al. 2017). The need for further studies that will evaluate Wnt-5a therapeutic 
potential and its suitability as a biomarker in periodontitis has been expressed in the 
literature (Maekawa et al. 2017, Nanbara et al. 2017). Currently, no available study has 
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evaluated the protein levels of Wnt-5a in the GCF of chronic periodontitis patients. 
Therefore, our findings cannot be compared with the results of other research 
investigators.  
 
In the present investigation, significant differences were found between the sampled sites 
in the periodontitis group in regards to the protein levels of Wnt-5a. Diseased sites in a 
group of periodontitis patients exhibited statistically significantly higher levels of Wnt-5a 
when compared to healthy sites of the same patients. This confirms our hypothesis that 
sites with periodontal destruction have increased Wnt-5a in the GCF. On the other hand, 
when sites in periodontitis and healthy patients were compared with respect to the total 
amounts of Wnt-5a, no significant differences were detected. This finding could possibly 
be a result of the age differences between the study groups. Evidence of differences in 
the expression of WNT genes between young and aged individuals has been reported in 
the literature when mesenchymal stem cells were obtained (Shen et al. 2009). More 
specifically, an increased WNT gene expression was shown in a young group when 
compared to an aged group. Furthermore, mature osteoblasts of aged mice have 
demonstrated decreased expression of Wnt-5a compared with those of young mice 
(Rauner et al. 2008, Becerikli et al. 2017). Therefore, the lack of association between the 
healthy and periodontitis group in our study may be attributed to the significantly younger 
age of the control as compared to the periodontitis group. Obesity has also been 
associated with elevated levels of Wnt-5a in humans when compared to lean controls 
(Schulte et al. 2012). In the present study, no information was recorded in regard to body 
mass index of the included population.  
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TNF is considered a major inflammatory mediator with two ligands. It is produced by 
phagocytes and T cells in response to bacteria and especially lipopolysaccharide leading 
to periodontal destruction (Ebersole and Cappelli 2000). TNF-Į affects the expression of 
other inflammatory mediators including IL-1, PGE2 and MMP (Ebersole and Cappelli 
2000; Cekici et al. 2014). It is involved in recruiting leukocytes to inflamed tissues, vascular 
permeability and leakage and chemokine production (Hofmann et al. 2002, Frank et al. 
1995). In the present investigation, the protein levels of TNF-Į were similar between 
periodontitis and healthy patients as well as when periodontitis and healthy sites were 
compared in a periodontitis subgroup. In this study, a wide range of TNF-Į levels in both 
periodontitis and healthy sites were also found. This may be related to the clinical 
variability among the sampled sites. The lack of association between periodontal status 
and TNF-Į GCF levels could be explained by the disease activity at the time of the 
sampling.  Perhaps the active inflammatory process due to the chronicity of the disease 
might have weakened. 
 
Previous studies have shown contradictory results. In a study by Reis et al. (2014) TNF-Į 
levels were significantly higher in diseased sites compared to non-diseased sites (Reis et 
al. 2014). In comparison to our study, Reis et al. considered only PPD to define chronic 
periodontal disease while it is unclear the criteria used for non-diseased sites.  Gokul and 
colleagues (2012) compared gingivitis, chronic periodontitis and healthy individuals 
showing that there was a highly significant difference between healthy subjects when 
compared to the other two groups, while no significant differences were detected between 
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gingivitis and periodontitis groups (Gokul et al. 2014). TNF-Į may also be present in 
normal gingival tissues and may be related to physiological activities. Healthy gingival 
tissues exhibit a low number of macrophages and mononuclear cells and GCF includes 
neutrophils in a healthy periodontium which may explain the presence of TNF-Į in healthy 
sites (Page 1991). The variability of findings among the studies may be attributed to the 
different inclusion criteria used for the groups. In the present investigation, no restriction 
was applied to the healthy patients as far as gingival inflammation was concerned. 
Therefore, patients included in the healthy group might also have gingival inflammation. 
As a result, presence of high numbers of inflammatory cells in the connective tissue and 
gingival crevice may up-regulate TNF-Į upon stimulation by the bacterial products (Page 
1991). High GCF TNF-Į levels have also been found in a healthy periodontium (Ulker et 
al. 2008). Rossomando and colleagues (1990) suggested that TNF-Į may be found in 
sites prior to clinically observable disease which may explain these results. 
 
In general, differences in the findings among studies utilizing GCF samples may be 
attributed to different parameters. First of all, the vast majority of the studies have used 
paper strips which are efficient and easy to insert into the gingival sulcus or periodontal 
pocket. This method can lead to a higher absorption of the GCF than using paper points. 
In a study by Guentch and colleagues, the use of paper strips resulted in higher cytokine 
levels when compared to paper points (Guentch et al. 2011). In addition, the time of GCF 
collection varies from 30 seconds to 1 minute. In the present study, paper strips were 
inserted into the sulcus or pocket for 30 seconds in order to reduce the risk of blood or 
saliva contamination. Moreover, different GCF analytic methods have been employed. 
85 
 
The majority of the GCF studies have used the ELISA technique, while others have 
performed the immunofluorometric assay (IFMA) which was shown by Leppilahti et al. 
(2014) to be more accurate than using ELISA. Another important parameter is the use of 
different diagnostic criteria for periodontal disease and health as well as the collection of 
a limited number of samples from each individual. The use of different inclusion criteria 
based on disease status increases the heterogeneity of the studies and does not allow for 
accurate comparisons between them which may explain the controversial findings. 
Collection of a small number of samples per patient may not permit a precise evaluation 
and analysis of the protein total levels or concentrations associated with periodontal 
disease and health due to the fact that the development of periodontitis is site-specific 
(Fujita et al. 2012). 
 
In an attempt to compare the protein levels of SOST, Wnt-5a and TNF-Į in GCF of 
diseased and healthy sites from patients with a generalized form of chronic periodontitis 
and periodontal health, “strict” criteria were used to define periodontitis and health. PPD, 
CAL and BOP were taken into consideration and patients with ≥ γ0% of the sites with PPD 
≥ 4 mm, CAL ≥ γ mm and presence of BOP were included in a periodontitis subgroup 
(n=10). Similarly, patients with PPD ≤ γ mm, CAL ≤ 1mm and BOP ≤ 15% were included 
in a healthy subgroup (n=10). The statistical analysis revealed that the protein levels of 
SOST, Wnt-5a and TNF-Į were higher in the periodontitis group when compared to the 
healthy. The results obtained from this subgroup analysis confirmed the initial hypothesis 
of the present investigation. However, only the comparison between the two groups in 
regards to SOST total amounts reached the significant level (p = 0.002). Future studies 
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should include a greater number of patients with a generalized form of chronic periodontitis 
(≥ γ0% of the sites), and BOP should also be considered when periodontitis and healthy 
individuals are recruited. 
 
Self-reported medical history and smoking status was utilized in the present investigation. 
Smoking status was recorded as an independent variable, while medical history was used 
to determine the eligibility of the patients to participate in the study based on the inclusion 
and exclusion criteria. Laboratory and/or physical examinations were not possible to be 
conducted in the Graduate Periodontology clinic of the University of Minnesota School of 
Dentistry, but self-reported measures have been used extensively in the literature and 
presents a cost effective and reliable method (Wada et al. 2009, Kehoe et al. 1994). Using 
patient self-reported data may be relatively faster, easier and less expensive than 
requesting a medical record examination, but there are limitations due to bias in patient 
recall, untruthful responses as a result of social desirability and a patient’s lack of 
knowledge (Newell et al. 1999). However, self-reported measures are accurate for chronic 
conditions and routine screening exams and may also provide valuable information for 
broad measures of population prevalence (Martin et al. 2000). Self-reported history of 
hypertension, diabetes and angina have shown generally high validity, whereas self-
reported hypercholesterolemia should be used with caution (Natarajan et al. 2002, Lampe 
et al. 1999, Robinson et al. 1997). It is generally believed that the variability by medical 
conditions may be derived from poor communication between physicians and patients due 
to the fact that diseases with clear diagnostic criteria such as diabetes, hypertension and 
myocardial infarction demonstrated higher rates of agreement than those that are difficult 
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for the patient to understand such as heart failure (Okura et al. 2004). It should also be 
expected that patients with impaired memory, psychological problems, psychiatric 
disorders and distortion of reality may result in decreased accuracy of a self-reported 
history (Johnson-Greene et al. 1997). 
 
Radiographic evaluation is commonly used in confirming a periodontal diagnosis and 
provide additional information, essential in treatment planning. Radiographs are of 
paramount importance in determining the extent and severity of alveolar bone loss and 
detecting osseous lesions (Pihlstrom 2001). Widely used radiographic modalities have 
been utilized and include bitewing, periapical and panoramic radiography. A full-mouth 
intraoral series of radiographs is the appropriate radiographic method for evaluation of 
periodontal disease and especially generalized disease or a history of extensive dental 
treatment. Panoramic radiographs exhibit limitations such as superimposition and 
distortion of structures, blurring of anatomical structures, while the determination of bone 
levels and defect depths is limited. A panoramic radiograph may be used in conjunction 
with bitewing radiographs and selected periapical radiographs as an alternative option for 
an intraoral full-mouth series of intraoral radiographs (Mol 2004). However, in the present 
investigation, a full-mouth series of periapical radiographs in combination with horizontal 
or vertical bitewings was utilized to determine the eligibility of the examined individual for 
the study. Our decision is in agreement with the American Dental Association’s 
recommendations reporting that new patients that are adolescents with permanent 
dentition or adults (dentate or partially edentulous) should be exposed to a full-mouth 
intraoral radiographic examination when there is clinical evidence of generalized oral 
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disease or a history of extensive dental treatment (American Dental Association 2012). 
Bitewing radiography was also required in the present study because its sensor is placed 
parallel to the tooth leading to the most accurate radiographic projection of the level of the 
alveolar crest (Eley and Cox 1998, White et al. 2001). 
 
The normal bone height in relation to the CEJ varies between 1 mm and 3 mm, while a 
distance of 2 mm is more widely accepted in studies of patients with a healthy 
periodontium (Wong et al. 2007, Gargiulo et al. 1961, Lennon and Davies 1974). In the 
present study, the distance from the alveolar bone to the CEJ was subjectively measured 
and the overall root length from the CEJ to the root tip was also measured. The percentage 
of bone loss was then expressed as a ratio of the amount of bone loss to the overall root 
length taking into consideration the normal bone level and then equated to the severity of 
bone loss. Individuals were included in the periodontitis group if 40% of bone loss was 
radiographically evident, while no radiographically detected bone loss was needed for the 
healthy group. Direct digital radiography compared to conventional film-based radiography 
has shown numerous advantages such as adjustable contrast and brightness, less 
working time and less radiation (Wenzel 1993). In the present study, direct digital 
radiographs were utilized to eliminate the limitations found with conventional modalities. 
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CONCLUSIONS  
 
In conclusion, the aim of developing new diagnostics in Periodontology remains important 
to identify patients at risk of periodontal disease onset and progression. Based on this 
research project, the following conclusions can be made:  
1. SOST, Wnt-5a and TNF-Į are detectable in the GCF of periodontally healthy and 
compromised sites.  
2. Sites with chronic periodontitis showed similar protein total amounts of SOST, Wnt-
5a and TNF-Į when compared to sites with healthy periodontium.  
3. The concentrations of SOST, Wnt-5a and TNF-Į demonstrated increased 
variability among the sampled sites and significant differences should be 
considered with caution.  
4. Diseased sites in patients with chronic periodontitis exhibited significantly elevated 
total protein levels of Wnt-5a when compared to healthy sites in the same patients. 
No significant differences were detected with SOST and TNF-Į. 
5. SOST, Wnt-5a and TNF-Į demonstrated low diagnostic value of chronic 
periodontitis. 
6. In a subgroup analysis of patients with a generalized form of chronic periodontitis 
and periodontal health, the total protein levels of SOST were significantly higher in 
periodontitis than in healthy sites. No significant differences were found in regards 
to Wnt-5a and TNF-Į. However, a small sample group (n=10) was used for this 
subgroup analysis.  
90 
 
7. Increased diagnostic value was detected when patients with a generalized 
moderate and severe form of chronic periodontitis were evaluated. 
8. GCF SOST total amounts were significantly positively correlated or demonstrated 
a trend towards a positive correlation with the full mouth mean of PPD, CAL and 
the percentage of sites with PPD 4-6 mm. A trend towards a negative correlation 
was found between SOST and sites with a CAL 0-2 mm.  
9. Future studies should employ “strict” diagnostic criteria and recruit patients 
diagnosed with a generalized moderate and severe form of chronic periodontitis 
and periodontal health. These studies should aim to further evaluate the findings 
of the subgroup analysis in the present study and determine the diagnostic value 
of screening patients with moderate and severe chronic periodontitis.  
10. Longitudinal studies should evaluate the prognostic value of SOST, Wnt-5a and 
TNF-Į in chronic periodontitis.  
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Table 1: Demographic characteristics of the total population as well as the 
periodontitis and healthy groups 
 
 
 
 
* Statistical significance between study groups with p-value < 0.05. 
† T-test was used to compare the mean age between the study groups.  
‡ Chi-square test was used to compare categorical variables including gender, race, 
smoking status, type of smoking, amount of smoking between the study groups.  
 
 
Characteristics Periodontitis 
group 
(N=25 – 50%) 
Healthy  
group 
(N=25 – 50%) 
Total  
population 
(N=50 – 100%) 
p-value* 
Age  
Mean (SD) 
 
57.9 (12.6) 
 
28.9 (10.2) 
 
43.4 (18.5) 
< 0.001† 
Gender 
Males (%) 
Females (%) 
 
12 (24) 
13 (26) 
 
6 (12) 
19 (38) 
 
18 (36) 
32 (64) 
0.077 ‡ 
Race 
Caucasians (%) 
African-Americans (%) 
Asians (%) 
Hispanics (%) 
 
18 (36) 
5 (10) 
0 (0) 
2 (4) 
 
22 (44) 
1 (2) 
2 (4) 
0 (0) 
 
40 (80) 
6 (12) 
2 (4) 
2 (4) 
0.070 ‡ 
Smoking status 
Never smokers (%) 
Ex-smokers (%) 
Current smokers (%) 
 
10 (20) 
6 (12) 
9 (18) 
 
25 (50) 
0 (0) 
0 (0) 
 
35 (70) 
6 (12) 
9 (18) 
< 0.001 ‡ 
Type of smoking 
Cigarettes (%) 
Cigars (%) 
Pipe (%) 
Chewing tobacco (%) 
 
9 (100) 
0 (0) 
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
9 (100) 
0 (0) 
0 (0) 
0 (0) 
1.00 ‡ 
Amount of smoking 
<10 cig/day (%) 
10-20 cig/day (%) 
>20 cig/day (%) 
 
5 (55.5) 
4 (44.4) 
1 (11.1) 
 
0 (0) 
0 (0) 
0 (0) 
 
5 (55.5) 
4 (44.4) 
1 (11.1) 
1.00 ‡ 
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Table 2: Periodontal status of the total population as well as the periodontitis and 
healthy group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Statistical significance between study groups with p-value < 0.05. T-test was used to 
compare the mean values between the study groups. 
 
Abbreviations: 
PPD: Probing Pocket Depth 
CAL: Clinical Attachment Level  
BOP: Bleeding On Probing 
PI: Plaque index 
Characteristics Periodontitis 
group 
(N=25 – 50%) 
Healthy  
group 
(N=25 – 50%) 
Total 
population 
(N=50 – 100%) 
p-value* 
PPD (mm) 3.57 ± 1.20  1.90 ± 0.34 2.73 ± 1.21 < 0.001 
CAL (mm) 3.44 ± 1.83  0.09 ± 0.09  1.76 ± 2.12 < 0.001 
BOP (%) 42.09 ± 30.34 12.71 ± 15.72  27.40 ± 28.14 < 0.001 
PI (%) 25.87 ± 32.21 2.74 ± 4.57 14.30 ± 25.59 0.001 
Missing teeth  4.04 ± 3.76 0.76 ± 1.36 2.40 ± 3.25 < 0.001 
PPD=1-3 mm (%) 61.43 ± 22.73 97.43 ± 4.66 79.42 ± 24.38 < 0.001 
PPD=4-6 mm (%) 28.92 ± 15.65  2.57 ± 4.66  15.74 ± 17.54 < 0.001 
PPD≥7 mm (%) 
 
9.35 ± 14.06  0.00 ± 0.00 4.68 ± 10.92 0.002 
CAL=0-2 mm (%) 43.21 ± 27.58 100.00 ± 0.00 71.61 ± 34.57 < 0.001 
CAL=3-4 mm (%) 28.35 ± 13.02 0.00 ± 0.00 14.17 ± 16.98 < 0.001 
CAL≥5 mm (%) 28.44 ± 25.12  0.00 ± 0.00  14.22 ± 22.70 < 0.001 
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Table 3: Probing pocket depth and clinical attachment level of sampled sites in 
healthy and periodontitis group. 
 
 
 
 
 
 
Abbreviations: 
PPD: Probing Pocket Depth 
CAL: Clinical Attachment Level  
 
 
 
 
 
 
  
 
 
 
 
Clinical 
parameters 
Site-periodontal 
status 
(Diseased/healthy) 
N Mean 
(mm) 
Standard 
deviation 
(mm) 
Minimum 
(mm) 
Maximum 
(mm) 
PPD Diseased in 
periodontitis  
25 6.56 1.73 5.00 12.00 
 Healthy in 
periodontitis 
14 2.50 0.52 2.00 3.00 
 Healthy in health 25 2.56 0.77 1.00 4.00 
CAL Diseased in 
periodontitis  
25 7.24 2.52 4.00 13.00 
 Healthy in 
periodontitis 
14 0.86 0.77 0.00 2.00 
 Healthy in health 25 0.12 0.33 0.00 1.00 
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Table 4: Bleeding on probing of sampled sites in healthy and periodontitis group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Site-Periodontal 
status 
(Diseased/healthy) 
Bleeding on probing   
Total Yes (%) No (%) 
Diseased in 
periodontitis  
 
23 (92.0) 2 (8.0) 25 (100.0) 
Healthy in 
periodontitis 
 
3 (21.4) 11 (78.6) 14 (100.0) 
Healthy in health 
 
5 (20.0) 20 (80.0) 25 (100.00) 
Total 31 (48.4) 33 (51.6) 64 (100.0) 
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Table 5: Protein levels and concentrations of SOST, Wnt-5a and TNF-Į of 
periodontitis and healthy patients. 
 
 
 
 
 
 
 
 
 
 
 
 
* Statistical significance between study 
groups with p-value < 0.05. Mann–
Whitney U test was used to compare 
protein total amounts and concentrations 
between healthy patient sites and 
diseased sites in periodontitis patients. 
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Table 6: Protein levels and concentrations of SOST, Wnt-5a and TNF-Į of 
diseased sites and healthy sites in periodontitis patients 
 
 
 
 
* Statistical significance between study 
groups with p-value < 0.05. Wilcoxon 
signed-rank test was utilized to compare 
diseased sites and healthy sites in a 
subset of periodontitis patients that 
exhibited both diseased and healthy 
sites. 
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Table 7: Spearman’s rank correlations (rho) between protein total levels of 
SOST, Wnt-5a and TNF-Į with the periodontal clinical and age parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 
PPD: Probing Pocket Depth 
CAL: Clinical Attachment Level  
 
 
Parameters Protein levels 
SOST Wnt-5a TNF-Į 
PPD (full mouth) r = 0.29  
p = 0.044 
r = 0.01  
p = 0.936 
r = -0.26  
p = 0.071 
CAL (full mouth) r = 0.36  
p = 0.010 
r = 0.10  
p = 0.507 
r = -0.21  
p = 0.134 
PPD (sampled sites) r = 0.30  
p=0.037 
r = -0.08  
p = 0.589 
r = -0.29  
p = 0.039 
CAL (sampled sites) r = 0.21  
p = 0.139 
r = 0.01  
p = 0.950 
r = -0.26  
p = 0.073 
PPD=1-3 mm r = -0.34 
p = 0.017 
r = -0.04 
p = 0.773 
r = 0.26 
p = 0.066 
PPD=4-6 mm r = 0.33 
p = 0.018 
r = 0.04 
p = 0.771 
r = -0.23 
p = 0.107 
PPD≥7 mm r = 0.24 
p = 0.100 
r = 0.03 
p = 0.844 
r = -0.27 
p = 0.059 
CAL=0-2 mm r = -0.28 
p = 0.052 
r = -0.14 
p = 0.325 
r = 0.16 
p = 0.265 
CAL=3-4 mm r = 0.26 
p = 0.067 
r = 0.06 
p = 0.666 
r = -0.16 
p = 0.254 
CAL≥5 mm r = 0.26 
p = 0.070 
r = 0.12 
p = 0.402 
r = -0.18 
p = 0.219 
Age r = 0.27   
p = 0.055 
r = -0.01  
p = 0.962 
r = -0.28  
p = 0.052 
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Table 8: Spearman’s rank correlation (rho) between concentrations of SOST, 
Wnt-5a and TNF-Į with the periodontal clinical and age parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 
PPD: Probing Pocket Depth 
CAL: Clinical Attachment Level  
 
 
 
Parameters Concentrations 
SOST Wnt-5a TNF-Į 
PPD (full-mouth) r = -0.49  
p = 0.001 
r = -0.39  
p = 0.006 
r = -0.51  
p = 0.001 
CAL (full-mouth) r = -0.51  
p = 0.001 
r = -0.44  
p =0.001 
r = -0.58  
p < 0.001 
PPD (sampled sites) r = -0.52  
p < 0.001 
r = -0.39  
p = 0.006 
r = -0.49  
p = 0.001 
CAL (sampled sites) r = -0.57  
p < 0.001 
r = -0.38  
p = 0.007 
r = -0.52  
p < 0.001  
PPD=1-3 mm r = 0.47 
p = 0.001 
r = 0.37 
p = 0.008 
r = 0.53 
p < 0.001 
PPD=4-6 mm r = -0.46 
p = 0.001 
r = -0.33 
p = 0.021 
r = -0.47 
p = 0.001 
PPD≥7 mm r =-0.48 
p < 0.001 
r = -0.38 
p = 0.007 
r = -0.52 
p = 0.001 
CAL=0-2 mm r = 0.61 
p < 0.001 
r = 0.34 
p = 0.015 
r = 0.55 
p < 0.001 
CAL=3-4 mm r = -0.59 
p < 0.001 
r = -0.34 
p = 0.016 
r = -0.54 
p < 0.001 
CAL≥5 mm r = -0.63 
p < 0.001 
r = -0.38 
p = 0.006 
r = -0.55 
p < 0.001 
Age r =-0.47  
p =0.001 
r = -0.44  
p = 0.001 
r = -0.52  
p < 0.001 
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Table 9: Protein total levels of SOST, Wnt-5a and TNF-Į in sites with presence 
and absence of bleeding on probing 
 
 
 
 
 
 
 
 
 
 
 
* Statistical significance between sites with and without bleeding on probing with p-value 
< 0.05. Mann–Whitney U test was used to compare the median values between the 
groups. 
 
 
 
 
 
 
 
Protein total levels Bleeding on probing p-value* 
Presence 
(n=28) 
Absence 
(n=22) 
SOST (pg) 
Mean ± SD 
(Median) 
 
135.7 ± 36.3 
(135.5) 
 
122.1 ± 52.2 
(115.0) 
0.035 
Wnt-5a (ng) 
Mean ± SD 
(Median) 
 
1.9 ± 0.9 
(1.9) 
 
2.2 ± 1.0 
(2.5) 
0.265 
TNF-Į (pg) 
Mean ± SD 
(Median) 
 
32.2 ± 17.0 
(27.3) 
 
38.2 ± 17.1 
(38.0) 
0.194 
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Table 10: Protein levels and concentrations of SOST, Wnt-5a and TNF-Į with 
respect to gender 
 
 
 
* Statistical significance between males and females with p-value < 0.05. Mann–Whitney 
U test was used to compare the median values between the groups. 
 
 
 
 
Levels of SOST, 
Wnt-5a and TNF-Į  
Proteins Gender p-value* 
Males 
(n=18) 
Females 
(n=32) 
 
Total protein SOST (pg) 
Mean ± SD 
(Median) 
 
133.6 ± 48.2 
(130.7) 
 
127.6 ± 42.2 
(135.0) 
0.642 
 Wnt-5a (ng) 
Mean ± SD 
(Median) 
 
2.5 ± 1.1 
(2.5) 
 
1.8 ± 0.8 
(1.6) 
0.031 
 TNF-Į (pg) 
Mean ± SD 
(Median) 
 
34.0 ± 17.3 
(28.7) 
 
35.3 ± 17.3 
(32.9) 
0.777 
Concentrations of 
proteins 
SOST (pg/ȝL) 
Mean ± SD 
(Median) 
 
575.6 ± 1750.1 
(92.6) 
 
506.0 ± 1454.2 
(147.9) 
0.166 
 Wnt-5a 
(ng/mL) 
Mean ± SD 
(Median) 
 
13,950.4 ± 31075.5 
(2559.8) 
 
10,772.8 ± 25383.4 
(3502.3) 
0.307 
 TNF-Į 
(pg/ȝL) 
Mean ± SD 
(Median) 
 
320.5 ± 834.6 
(62.5) 
 
276.1 ± 599.9 
(54.9) 
0.709 
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Table 11: Protein total levels of SOST, Wnt-5a and TNF-Į of periodontitis and 
healthy groups using “strict” criteria for diagnosing periodontal disease and 
health. 
 
 
 
 
* Statistical significance between study groups with 
p-value < 0.05. Mann–Whitney U test was used to 
compare protein total amounts between 
periodontally healthy (n=10) patient sites and 
diseased sites in periodontitis patients (n=10) using 
“strict” diagnostic criteria.  
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Figure 1: Bone remodeling cycle  
 
 
 
 
 
 
 
Adapted from: Wittkowske C, Reilly GC, Lacroix D and Perrault CM (2016) In Vitro Bone 
Cell Models: Impact of Fluid Shear Stress on Bone Formation. Front. Bioeng. Biotechnol. 
4:87. doi: 10.3389/fbioe.2016.00087 
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Figure 2: Effect of Wnt signaling pathway on bone mass regulation 
 
 
 
 
 
 
 
 
 
 
Adapted from: Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: 
from human mutations to treatments. Nat Med. 2013 Feb;19(2):179-92. 
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Figure 3: Interaction between Wnt/ȕ-catenin signaling and bone cells 
 
 
 
 
 
 
 
Adapted from: Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: 
from human mutations to treatments. Nat Med. 2013 Feb;19(2):179-92. 
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Figure 4: Overview of the Wnt signaling 
 
 
 
 
 
 
 
Adapted from: Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: 
from human mutations to treatments. Nat Med. 2013 Feb;19(2):179-92. 
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Figure 5: Regulation of secretion of the WNT inhibitor, SOST, from osteocytes 
inactivates the Wnt/ ȕ-catenin signaling 
 
 
 
 
Adapted from: Burgers TA, Williams BO. Regulation of Wnt/ȕ-catenin signaling within 
and from osteocytes. Bone. 2013 Jun;54(2):244-9. 
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Figure 6: A schematic diagram showing the role of SOST in Wnt/ȕ-catenin and 
RANKL/RANK. 
 
 
 
 
 
Adopted from: Diao X, Li Z, An B, Xin H, Wu Y, Li K, Feng F, Dou C. The Microdamage 
and Expression of Sclerostin in Peri-implant Bone under One-time Shock Force 
Generated by Impact. Sci Rep. 2017 Jul 26;7(1):6508.  
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Figure 7: Wnt-5a can both activate and inhibit the canonical Wnt signaling 
depending on the receptor context 
 
 
 
 
 
Adopted from: Leris A, Roberts T, Jiang W, Newbold R, Mokbel K. 2005. WNT-5A 
expression in human breast cancer. Anticancer Res 25:731–734. 
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Figure 8: Distribution of the total amount of GCF SOST in the study groups. Dark 
lines show medians. 
 
 
 
 
 
 
 
Mann-Whitney U test was used to compare the protein total amounts of SOST between 
chronic periodontitis (n=25) and periodontally healthy (n=25) sites in chronic periodontitis 
and healthy patients, respectively. No significant differences were found between the 
two groups (p=0.068). 
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Figure 9: Distribution of the total amount of GCF Wnt-5a in the study groups. 
Dark lines show medians. 
 
 
 
 
 
 
Mann-Whitney U test was used to compare the protein total amounts of Wnt-5a between 
chronic periodontitis (n=25) and periodontally healthy (n=25) sites in chronic periodontitis 
and healthy patients, respectively. No significant differences were found between the 
two groups (p=0.854). 
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Figure 10: Distribution of the total amount of GCF TNF-Į in the study groups. 
Dark lines show medians. 
 
 
 
 
 
 
 
 
Mann-Whitney U test was used to compare the protein total amounts of TNF-Į between 
chronic periodontitis (n=25) and periodontally healthy (n=25) sites in chronic periodontitis 
and healthy patients, respectively. No significant differences were found between the 
two groups (p=0.071). 
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Figure 11a: Distribution of the concentration of GCF SOST in the study groups. 
Dark lines show medians. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mann-Whitney U test was used to compare the concentrations of SOST between chronic 
periodontitis (n=25) and periodontally healthy (n=25) sites in chronic periodontitis and 
healthy patients, respectively. Statistically significant differences were found between the 
two groups (p<0.001). 
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Figure 11b: Distribution of the concentration of GCF SOST in the study groups 
after removing two observational points (sampled sites) that are distant from the 
other observations. Dark lines show medians. 
 
 
 
 
 
 
 
 
 
114 
 
Figure 12: Distribution of the concentration of GCF Wnt-5a in the study groups. 
Dark lines show medians. 
 
 
 
 
 
 
 
Mann-Whitney U test was used to compare the concentrations of Wnt-5a between 
chronic periodontitis (n=25) and periodontally healthy (n=25) sites in chronic periodontitis 
and healthy patients, respectively. Statistically significant differences were found 
between the two groups (p=0.003). 
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Figure 13: Distribution of the concentrations of GCF TNF-Į in the study groups. 
Dark lines show medians. 
 
 
 
 
 
 
Mann-Whitney U test was used to compare the concentrations of TNF-Į between 
chronic periodontitis (n=25) and periodontally healthy (n=25) sites in chronic periodontitis 
and healthy patients, respectively. Statistically significant differences were found 
between the two groups (p<0.001). 
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Figure 14: Distribution of the total amounts of GCF SOST of the diseased and 
healthy sites in periodontitis patients. Dark lines show medians. 
 
 
 
 
 
 
Wilcoxon signed-rank test was used to compare the protein total amounts of SOST 
between diseased sites and healthy sites in a subset of chronic periodontitis patients 
(n=14) that exhibited both diseased and healthy sites. No significant differences were 
found between the two groups (p=0.413). 
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Figure 15: Distribution of the total amounts of GCF Wnt-5a of the diseased and 
healthy sites in periodontitis patients. Dark lines show medians. 
 
 
 
 
 
Wilcoxon signed-rank test was used to compare the protein total amounts of Wnt-5a 
between diseased sites and healthy sites in a subset of chronic periodontitis patients 
(n=14) that exhibited both diseased and healthy sites. Statistically significant differences 
were found between the two groups (p=0.017). 
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Figure 16: Distribution of the total amounts of GCF TNF-Į of the diseased and 
healthy sites in periodontitis patients. Dark lines show medians. 
 
 
 
 
 
 
Wilcoxon signed-rank test was used to compare the protein total amounts of TNF-Į 
between diseased sites and healthy sites in a subset of chronic periodontitis patients 
(n=14) that exhibited both diseased and healthy sites. No statistically significant 
differences were found between the two groups (p=0.194). 
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Figure 17a: Distribution of the concentrations of GCF SOST of the diseased and 
healthy sites in periodontitis patients. Dark lines show medians. 
 
 
 
 
 
 
Wilcoxon signed-rank test was used to compare the concentrations of SOST between 
diseased sites and healthy sites in a subset of chronic periodontitis patients (n=14) that 
exhibited both diseased and healthy sites. Statistically significant differences were found 
between the two groups (p=0.001). 
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Figure 17b: Distribution of the concentrations of GCF SOST of the diseased and 
healthy sites in periodontitis patients after removing an observational point 
(sampled site) that is distant from the other observations. Dark lines show 
medians. 
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Figure 18a: Distribution of the concentrations of GCF Wnt-5a of the diseased and 
healthy sites in periodontitis patients. Dark lines show medians. 
 
 
 
 
 
 
 
Wilcoxon signed-rank test was used to compare the concentrations of Wnt-5a between 
diseased sites and healthy sites in a subset of chronic periodontitis patients (n=14) that 
exhibited both diseased and healthy sites. Statistically significant differences were found 
between the two groups (p=0.001). 
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Figure 18b: Distribution of the concentrations of GCF Wnt-5a of the diseased and 
healthy sites in periodontitis patients after removing an observational point 
(sampled site) that is distant from the other observations. Dark lines show 
medians. 
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Figure 19: Distribution of the concentrations of GCF TNF-Į of the diseased and 
healthy sites in periodontitis patients. Dark lines show medians. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wilcoxon signed-rank test was used to compare the concentrations of TNF-Į between 
diseased sites and healthy sites in a subset of chronic periodontitis patients (n=14) that 
exhibited both diseased and healthy sites. Statistically significant differences were found 
between the two groups (p=0.001). 
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Figure 20: ROC analysis of total amounts of GCF SOST to diagnose chronic 
periodontitis.  
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Figure 21: ROC analysis of total amounts of GCF Wnt-5a to diagnose chronic 
periodontitis.  
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Figure 22: ROC analysis of total amounts of GCF TNF-Į to diagnose chronic 
periodontitis.  
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Figure 23: Distribution of the total amounts of GCF SOST of the diseased and 
healthy sites in the strictly diagnosed periodontitis and healthy patients. Dark 
lines show medians.  
 
 
 
 
Mann-Whitney U test was used to compare the total amounts of SOST between chronic 
periodontitis (n=10) and periodontally healthy (n=10) sites in strictly diagnosed chronic 
periodontitis and healthy patients, respectively. Statistically significant differences were 
found between the two study subgroups (p=0.002). 
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Figure 24: Distribution of the total amounts of GCF Wnt-5a of the diseased and 
healthy sites in the strictly diagnosed periodontitis and healthy patients. Dark 
lines show medians.  
 
 
 
 
 
 
Mann-Whitney U test was used to compare the total amounts of Wnt-5a between chronic 
periodontitis (n=10) and periodontally healthy (n=10) sites in strictly diagnosed chronic 
periodontitis and healthy patients, respectively. No significant differences were found 
between the two study subgroups (p=0.070). 
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Figure 25: Distribution of the total amounts of GCF TNF-Į of the diseased and 
healthy sites in the strictly diagnosed periodontitis and healthy patients. Dark 
lines show medians.  
 
 
 
 
 
Mann-Whitney U test was used to compare the total amounts of TNF-Į between chronic 
periodontitis (n=10) and periodontally healthy (n=10) sites in strictly diagnosed chronic 
periodontitis and healthy patients, respectively. No significant differences were found 
between the two study subgroups (p=0.226). 
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Figure 26: ROC analysis of total amounts of GCF SOST to diagnose generalized 
chronic periodontitis.  
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Figure 27: ROC analysis of total amounts of GCF Wnt-5a to diagnose 
generalized chronic periodontitis.  
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Figure 28: ROC analysis of total amounts of GCF TNF-Į to diagnose generalized 
chronic periodontitis.  
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